




EXPLORING THE ROLE OF ELEVATED LIPID PEROXIDATION AND 
GLUTATHIONE PEROXIDASE 4 IN METABOLIC SYNDROME AND 
CARDIAC REMODELING IN OBESITY 
By 
 




Director of Dissertation: Dr. Ethan J. Anderson 
Department of Pharmacology and Toxicology, Brody School of Medicine, East Carolina 
University 
ABSTRACT 
Cardiovascular disease continues to be a leading cause of global mortality. Metabolic 
perturbations including obesity, hyperlipidemia and type II diabetes arising from a 
western style diet and a more sedentary lifestyle are significant contributors to this 
phenomenon. Diabetic patients are at a significantly higher risk of developing heart 
disease. Approximately 50% of diabetic patients suffer from cardiomyopathy and they 
are twice as likely to develop congestive heart failure.  Importantly, this cardiomyopathy 
is often independent of hypertension and coronary artery disease, suggesting that 
factors inherent to the metabolic disease are pathogenic to the heart. Mitochondrial 





development of diabetic cardiomyopathy and heart failure. Studies on diabetic hearts 
reveal these mitochondria have increased reactive oxygen species (ROS) emission, 
reduced ATP production and oxidative damage. At a gross scale, an early histological 
finding in the hearts of a sub-set of both diabetic and obese patients is increased 
collagen deposition and an infiltration of fibroblasts which over time leads to reduced 
cardiac compliance/ relaxation and ultimately diastolic dysfunction.   
Lipid peroxides and reactive aldehyde derivatives (LPPs) are derived from ROS 
peroxidation of cellular polyunsaturated fatty acids and have been linked to 
cardiometabolic disease. The objective of this study was to test the hypothesis that 
LPPs underlie cardiometabolic derangements in obesity. This hypothesis was tested 
using glutathione peroxidase 4 haploinsufficent (GPx4+/-) mice. GPx4 is one of the few 
enzymes specialized to neutralize lipid peroxides. GPx4 +/- mice were fed a high fat, 
high sucrose (HFHS) diet to investigate cardiometabolic derangements in a model of 
increased LPP production. Our research revealed that greater carbonyl stress, 
exacerbated glucose intolerance, dyslipidemia, and liver steatosis occurred in GPx4 +/- 
mice compared to wild-type (WT) on a high fat high sucrose diet (HFHS). Although 
normotensive, cardiac hypertrophy was evident with obesity, and cardiac fibrosis was 
more pronounced in obese GPx4 +/- mice. Mitochondrial dysfunction manifesting as 
decreased fat oxidation capacity and increased reactive oxygen species was also 
present in obese GPx4 +/- but not WT hearts, along with up-regulation of pro-
inflammatory and pro-fibrotic genes.  Biochemical analysis was also performed on 





hyperglycemia exhibited significantly less GPx4 enzyme and greater HNE-adducts in 
their hearts, compared with age-matched non-diabetic patients.  
 The pathogenic role of LPPs was further investigated using carnosinol (CAR), an 
LPP scavenger that preferentially binds and sequesters reactive aldehydes.  In this 
follow-on study, CAR was administered via drinking water (40mg/kg) starting mid-way 
through the HFHS diet. In WTs, CAR improved whole body glucose tolerance, blood 
lipid profiles and insulin sensitivity. CAR treatment also mitigated HFHS- diet induced 
cardiac hypertrophy and hepatic steatosis. Levels of 4-HNE adducts were reduced in 
the cardiac mitochondria, liver and whole heart following treatment. Mitochondrial 
oxidative phosphorylation efficiency (OxPhos) in the heart was also improved with CAR 
in WT mice fed HFHS diet, although no effect on mitochondria in the GPx4+/- mice was 
observed. Collectively, the data presented in this dissertation provide evidence that lipid 
peroxides and their reactive aldehyde derivatives are a distinct form of oxidative stress 
that has an etiological role in human cardio-metabolic disease. It establishes that GPx4 
is an adaptive response to oxidative stress in obesity, and that deficiency in this 
important enzyme accelerates the pathogenic effect of the condition.  Furthermore, it 
provides support for the development of a novel class of aldehyde scavenging 
compounds to ameliorate the cardio-metabolic disease and associated comorbidities 
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Metabolic syndrome and diabetes 
The global prevalence of obesity is almost 30% (1, 2). Epidemiological forecasts project this 
increase to continue making obesity one of the most significant public health concerns (3). 
According to the World Health Organization (WHO), obesity is defined as having a BMI of 
≥30kg/m2. This increase in obesity prevalence is attributed largely to global dietary transition to 
a more western style diet in and a decline in physical activity (4). Obesity is part of a 
constellation of conditions, which include visceral adiposity, hyperglycemia, elevated serum 
triglycerides and high blood pressure (5). The manifestation of this cluster of conditions is called 
metabolic syndrome. Other risk factors for metabolic syndrome include age and race (6). 
 Obesity is also one of the most important risk factors that are associated with the 
development type II diabetes (TIIDM) later in life (6, 7). In TIIDM, there is a reduced sensitivity 
of the body’s tissues particularly key glucose uptake organs such as the liver, skeletal muscle 
and adipose tissue to insulin. The hormone insulin is produced by the β-cells of the pancreas 
and once it binds to insulin receptors in peripheral tissues it stimulates increased uptake of 
glucose (8). In the early stages of TIIDM disease progression known as insulin resistance or 
prediabetes there is a progressively more suppressed tissue response to insulin stimulation and 
to compensate, the pancreas produces greater amounts of insulin in a positive feedback loop 
(9-12). It must be noted that not all patients who present with insulin resistance progress to 
TIIDM, indeed there is a subset of patients known as healthy obese where this characteristic 
appears to be protective (13). Insulin resistance as a pathology is a complex tissue specific 
interplay of the deleterious effects of chronically elevated levels of glucose and insulin. In the 
1950s the association between diabetes and heart disease was first identified through 






     
 
Diabetes and Heart Disease 
The hallmarks of diabetic cardiomyopathy are ventricular hypertrophy and diastolic dysfunction 
(16-18).  Early diabetic cardiomyopathy is characterized by cardiac stiffness from excess fibrotic 
deposition and this is often evident early in the progression of disease (19). Increased cardiac 
stiffness leads to decreased compliance of the left ventricle resulting in a reduction in end-
diastolic volume (20).  Furthermore, complete ventricular relaxation requires sequestration of 
Ca2+ molecules at the end of excitation-contraction cycle in the cardiomyocyte. This process 
requires energy supplied from adenosine triphosphate (ATP) hydrolysis.  Numerous studies 
have demonstrated compromised both Ca 2+ handling and bioenergetic capacity in both human 
and murine diabetic hearts (21-24). Ultimately in many patients the symptoms result in 
symptomatic heart failure, which called Heart Failure with preserved ejection fraction (HfpEF).  
Patients with hypertension, angina or coronary arterial disease are at a high risk of developing 
this particular form heart failure. Diastolic dysfunction progresses over time as demonstrated in 
the Olmsted County Heart Function Study (OCHFS) therefore older patients are at higher risk 
(2.85 greater odds) and many often progress to heart failure (20). In a study of approximately 
1000 patients with an average age of 62 years, diastolic dysfunction was positively associated 
with HOMA-IR and metabolic syndrome (16).  The mechanisms that under the link between 
diabetes and the progression to clinical cardiomyopathy and eventually heart failure are poorly 
understood however one prominent finding is the metabolic perturbations observed in the 
diabetic heart. 
 
Lipid peroxidation and cellular damage 
The heart is a post-mitotic, highly oxidative organ in which cell turnover rates are virtually absent, 
so products formed from oxidative damage of tissue and cellular material accumulate with time.  




     
 
and age-related diseases such as diabetes and cardiovascular disease (25).  In fact, for all 
diseases where acute and chronic oxidative stress is either a causative factor or deleterious 
consequence, lipid peroxides are starting to take center stage as the most potent, persistent 
and physiologically relevant agents of this stress (25-27).  
Oxidation of membrane phospholipids, and other polyunsaturated fatty acids (PUFAs) 
that are stored or otherwise located in cardiomyocytes, is one of the most prominent 
manifestations of oxidative stress in the heart.  Indeed, with their long, chain-like structure and 
large number of unsaturated carbon-carbon bonds, PUFAs are some of the most readily 
oxidized chemicals in nature, occurring through enzymatic or non-enzymatic pathways.  Non-
enzymatic peroxidation of PUFAs, particularly those contained within membrane phospholipids, 
is typically initiated by electrophilic attack on one of the methylene carbons contained within the 
fatty acid side-chains.  Reactive oxygen (ROS) and nitrogen species (RNS) are the electrophiles 
most commonly involved in lipid peroxidation, and if allowed to proceed unchecked this reaction 
results in formation of both stable and unstable lipid peroxidation products (LPPs).  Of all the 
LPPs formed in this manner, reactive aldehydes have been shown to have regulatory roles in 
physiological systems, and have been implicated to play important roles in cardiovascular 
disease (28).   
Because of the insatiable appetite for nutrients and oxygen required to meet its energetic 
demands, the heart contains a very high mitochondrial content relative to other organs.  
Mitochondria are the largest source of intracellular ROS in cardiomyocytes (29), as superoxide 
(O2●─) is continuously formed at sites within the electron transport system during oxidative 
phosphorylation (OxPhos).  Furthermore, mitochondria are double membrane-bound organelles 
that have an enormous amount of unsaturated phospholipids contained within their inner and 
outer membranes, notably cardiolipin, a phospholipid exclusive to mitochondria that is highly 




     
 
are ostensibly the largest endogenous source of LPPs in the heart.  To offset the formation of 
LPPs, mitochondria have a vast network of antioxidant and detoxification systems, ensuring that 
lipid peroxidation and levels of reactive aldehydes are kept at subtoxic levels.  Over time, 
however, and under various pathological states, these antioxidant and aldehyde detoxification 
systems become compromised and/or lost, and the subsequent accumulation of LPPs and 
aldehydes has profound consequences for the function of mitochondria, the cardiomyocyte and 
the heart.   
 
Formation of LPPs and aldehydes in mitochondria.  
It has been known for decades that mitochondria generate ROS as a by-product of OxPhos (32).  
Mitochondrial O2●─ is formed when electrons ‘leak’ from the electron transfer system (ETS) in 
the mitochondria and are taken on by molecular oxygen (33).  The exact sites of O2●─ formation 
within the ETS are controversial but there is broad consensus that redox reactions within 
Complex I + III are both capable of producing O2●─ (shown in detail in Figure 1A), although 
which of these is the predominant site in vivo is far from clear (34, 35).  Most of this O2●─ is 
immediately converted to H2O2 by superoxide dismutase enzymes in either the mitochondrial 
matrix (MnSOD) or cytosol (Cu/ZnSOD).  In addition to the ETS, mitochondria also generate 
H2O2 from monoamine oxidase (MAO) bound to the outer membrane (33, 36).  MAO is the 
enzyme responsible for metabolism of catecholamines, and has recently been shown to be a 
substantial source of H2O2 and oxidative stress in heart failure (37).  MAO's unique orientation 
relative to the ETC provides the ability for MAO to interfere with mitochondrial function and 
cellular energetics, although very little is known about the potential contribution of MAO-derived 
ROS in cardio-metabolic diseases. One study reported that MAO-derived ROS led to diminished 
state 3 and state 5 respiration (38). Furthermore, Hauptmann and colleagues showed that 




     
 
demonstrated that H2O2, produced from MAO exposure to tyramine, can readily diffuse through 
the inner mitochondrial membrane and produce a significant increase in mtDNA single strand 
breaks (36). Because of MAO's proximity to the mitochondrial oxidative phosphorylation system, 
ROS produced by MAO could conceivably disrupt the ATP-dependent electrochemical and 
contractile functions of cardiomyocytes, given the heavy reliance on mitochondria for ATP in 
these cells (39, 40)  
Nitric oxide, as it exists with its unpaired electron (NO●), is also a free radical and can 
frequently react with O2●─ to form peroxynitrite ONOO●─.  Peroxynitrite is considered to be the 
chief RNS formed in physiological systems (41), and it is a highly reactive electrophile 
responsible for nitration and nitrosylation reactions with hydroxyl and thiol groups in proteins 
during periods of oxidative stress.  Though still a matter of some debate, several studies have 
reported the presence of a nitric oxide synthase (NOS) isoform within mitochondria, distinct from 
other established isoforms of NOS such as eNOS, nNOS and iNOS (42, 43) .  The presence of 
NOS within mitochondria, coupled to continuous O2●─ formation by the ETS would suggest that 
tight regulation of ONOO●─ formation and the presence of ONOO●─ scavenging systems are 
critical to maintaining homeostasis. 
Ultimately it is ONOO●-, in addition to hydroxyl radical OH●, formed via Fenton reaction of 
Fe2+ or Cu2+ with H2O2, that initiates lipid peroxidation by electrophilic attack on mitochondrial 
phospholipids.  Outlined in the dashed box in Figure 1 is the general reaction scheme of non-
enzymatic lipid peroxidation in mitochondria with initial step coming from OH● attack of 
unsaturated fatty acids contained within cardiolipin (step 1).  Following initiation by OH●, an 
unstable lipid radical is formed which can continue to abstract allylic hydrogens from nearby 
unsaturated fatty acids (step 2), or react with molecular O2 (step 3) to form a lipo-peroxyl radical 
that either continues on to react with another fatty acid forming a new radical, or reacts with 




     
 
suggested to be partly responsible for the altered cardiac function seen in the aged heart (44), 
likely through disruption in membrane order and dynamics in mitochondria leading to 
destabilization of cytochrome c and complexes within the ETS, all of which have profound 
effects on cell energetics and vitality (45, 46).   
If they are not neutralized by endogenous antioxidants, lipid peroxides will fragment and 
decompose to form reactive aldehydes such as di-aldehydes (malondialdehyde, MDA) and α,β-
unsaturated aldehydes (acrolein; 4-hydroxynonenal, HNE; and 4-hydroxyhexenal, HHE) (47).  
The 4-hydroxyalkenals formed from PUFA oxidation (HNE from n-6 PUFAs, HHE from n-3 
PUFAs) are highly reactive electrophiles capable of covalently modifying proteins, DNA and 
other macromolecules, similar to the ROS/RNS that spawned them, though they also have 
unique properties endowing them with distinct roles in biological systems.  They are uncharged, 
lipophilic and chemically stable molecules capable of readily diffusing through membranes.  In 
addition, some of the less hydrophobic aldehydes such as MDA, acrolein and HHE are able to 
diffuse fairly long distances from their sites of origin, enabling them to act as signaling mediators 
within cells and tissues under various physiological and pathological contexts (28).   
Mechanisms for scavenging LPPs and aldehydes.  Mitochondria are endowed with such a 
highly concentrated and layered antioxidant network that they can be considered to not only be 
primary ‘sources’ of ROS/RNS within cells, but also primary ‘sinks’ (33, 48).  This network 
includes glutathione and thioredoxin systems, along with peroxidases, catalase, superoxide 
dismutase, glutaredoxin, sulfiredoxin, peroxiredoxin, and others. (48-50). 
  
Mitochondria as a primary target of LPPs in heart 
To date, the majority of research directed at identifying molecular targets of LPPs has been 
conducted in models of cancer, neuronal disease or in purely cytotoxic (i.e. supra-physiological) 




     
 
lipid peroxidation may be a constitutive process that is fundamental to maintaining homeostasis, 
such as the heart (39). Studies of the effects of lipid peroxidation in cardiac tissue are sparse, 
even though this tissue may easily be considered to have the highest capacity for this process. 
Cardiomyocytes possess the highest mitochondrial density of all tissues in the body, therefore a 
higher capacity for ROS production. In addition to the high PUFA content distributed across the 
mitochondrial membrane, there is also an omnipresent pool of free fatty acids, the preferred 
substrate of cardiac mitochondria. This pool closely reflects dietary intake. According to some 
estimates the n-6: n-3 PUFA ratio approaches 10:1 in the archetypal Western diet (40).  Hence, 
HNE would be expected to constitute a much higher proportion of LPPs in individuals on such a 
diet. Approximately 2-8% of HNE(41) produced is involved in largely irreversible cell conjugation 
reactions with both cellular and mitochondrial proteins. The following sections shall discuss the 
resultant mitochondrial component damage and aberrations in homeostasis. 
 
LPP effects on cellular membranes.  
 The primary source of ROS in cardiomyocytes is the electron transport system located in the 
mitochondrial inner membrane (42). Thus, the most immediate target of the 4-hydroxyalkenals 
are the lipids present in the phospholipid bilayer (43, 44) and its associated proteins (45). The 
reaction of 4-hydroxyalkenals with the mitochondrial membrane results in altered lipid-lipid and 
protein-lipid interactions.  This occurs through a variety of mechanisms which include cross-
linking of the lipid tails which limits mobility of phospholipids in the bilayer (46). Of singular 
importance, the inner mitochondrial membrane mosaic contains a phospholipid, cardiolipin that 
is specifically localized to this compartment.  Its presence ensures the efficient function of a 
battery of mitochondrial components such as the electron transport chain complexes, adenine 
nucleotide transporter and the acylcarnitine carrier, among others (47, 48).  Cardiolipin levels 




     
 
cardiolipin have been observed in many pathological conditions including aging, Barth 
syndrome, heart failure, ischemia and reperfusion, diabetes and neurodegenerative disease 
(47). The mitochondrial membranes contain a high density of polyunsaturated fatty acids 
(PUFAs) and phospholipids, which are susceptible to peroxidation (52, 53). 
Phosphatidylethanolamine and phosphatidylcholine are the most abundant phospholipids and 
comprise ~40% and ~ 30% of total mitochondrial phospholipids, respectively. Cardiolipin and 
phosphatidylinositol (PI) account for ~ 10–15% of phospholipids, whereas phosphatidic acid (PA) 
and phosphatidylserine (PS) comprise ~ 5% of the total mitochondrial phospholipids. Cardiolipin 
is concentrated in the inner mitochondrial membrane in close proximity to the ETS. Although it 
comprises a relatively a low percentage of total membrane phospholipid, its peroxidation is 
directly associated with a decline in activity of respiratory complexes III and IV, and the release 
of cytochrome c which initiates apoptotic signaling (54-56). This is significant because 
cardiolipin is especially susceptible to peroxidation. 
In the event that 4-hydroxyalkenals migrate to the cell membrane, the high number of 
conjugated unsaturated carbon bonds in the cholesterol molecule make it an attractive target for 
attack (50). Collectively, studies on the effects on lipid peroxidation on membrane physiology 
demonstrate a marked reduction in membrane fluidity (46, 51, 52) and an increase in membrane 
permeability (53, 54).  Moreover, the production of 4-hydroxyalkenals via lipid peroxidation gives 
rise to a chain reaction. The products formed from electrophilic attack by the 4-hydroxyalkenals 
degrade to generate more aldehydes which serve to propagate the cycle (55). Some of the more 
stable products include isoprostanes and neuroprostanes following cyclization of the fatty acid 







     
 
LPP effects on cellular proteins.   
Enzymatic, structural and signaling proteins present in the phospholipid bilayer and 
mitochondrial matrix are a key target of 4-hydroxyalkenals.  Like all electrophiles, they have 
characteristic affinity for sulfhydryl groups (e.g. cysteine, methionine), although lysine and 
histidine are also subject to covalent modification in their amide groups (56-58) via Michael 
addition reactions (55). HNE augments the accumulation of damaged proteins by interfering 
with normal proteolysis pathways (59, 60). A recent proteomic study of the relative levels of 
adducted proteins in rat cardiac mitochondria treated with a spectrum of LPPs including HNE 
and HHE revealed that proteins of the electron transport chain constituted the greatest 
percentage of altered proteins. Moreover, this group observed that cysteine constituted an 
overwhelmingly high percentage of total modified residues (85%), while histidine accounted for 
12% and lysine less than 5% (61). Adduct levels for both HHE and HNE were relatively similar. 
This study underscores the high propensity that LPPs exhibit towards attacking protein 
components involved in cellular respiration (41, 62-64)(57), expanding our current knowledge of the 
negative impact of the LPPS on mitochondrial homeostasis.   
In addition to their direct effects, the 4-hydroxyalkenals are also indirectly capable of 
affecting mitochondrial homeostasis by disturbing the balance of ions (65, 66).  HNE attacks the 
sulfhydryl groups of the Na+/K+ ATPase (67) resulting in diminished activity and elevated 
intracellular concentrations of free calcium. Both HNE and HHE have been implicated in 
inducing Ca2+ overload in cardiomyocytes (68); activation of uncoupling proteins (69) and 
premature opening of the mitochondrial permeability transition pore (MTP) (70) thus increasing 
the risk of heart failure (3, 71). 
LPP effects on DNA and other cellular targets.  The role of the 4-hydroxyalkenals in 
DNA adduct formation during mutagenesis is well documented with respect to HNE.  HNE 




     
 
guanosine (72), cytosine, adenine, and least toward thiamine (73).  The cell machinery is capable 
of repairing damage to the DNA inflicted by LPPs by excising the damaged portion, although 
long-term exposure to LPPs leads to an accumulation of damaged DNA. In addition to its well-
documented reactivity with DNA, HNE is both directly and indirectly involved in the upregulation 
of several cell signaling pathways including Protein Kinase C, Mitogen Activated Protein 
Kinases, IκB Kinase Complex, Tyrosine receptor Kinases, Serine/ Threonine Kinase, C-Jun H-
Terminal Kinases (57, 71, 74-78). 
  
Compensatory Mechanisms for Adaptation to LPPs and Carbonyl Stress 
The diagram in Figure 1.2 shows the major enzymatic and non-enzymatic endogenous systems 
present in mitochondria and cytosol specific for neutralizing LPPs and aldehydes (i.e. 
scavenging LPPs and aldehydes once they have already been formed).  In most cell types, 
including heart, the major enzyme responsible for neutralizing lipid peroxides is glutathione 
peroxidase 4 (GPx4), also known as phospholipid hydroperoxide glutathione peroxidase (27, 28).  
This enzyme resides in cytosol, nucleus, and the inner membrane of mitochondria, where it 
utilizes glutathione (GSH) to reduce lipid peroxides to their corresponding alcohol.  GSH not 
only provides the reducing power for a large number of redox enzymes capable of reducing 
ROS (29), but it is also capable of neutralizing electrophilic lipids, such as HNE, after they are 
formed (30).  Esterbauer’s group showed that in heart, the conjugation of glutathione to HNE is 
catalyzed by the enzyme glutathione-transferase, resulting in export of this conjugate from the 
cell and into the systemic circulation (31).  The aldehyde dehydrogenase (ALDH) family of 
enzymes is also capable of neutralizing LPPs.  In particular, the cytosolic enzyme ALDH3a1, 
also called fatty aldehyde dehydrogenase (FALDH) (32), and ALDH2 (33), a mitochondrial matrix 
enzyme, are the 2 isoforms of ALDH that are most likely to be the enzymes responsible for 




     
 
a role.  ALDH converts aldehydes to acetate, rendering them far less reactive and virtually 
benign. 
In addition to the endogenous systems, chemical agents that have been demonstrated 
to have the capacity to neutralize LPPs and aldehydes are also presented in Figure 1.2  
Lipophilic antioxidants such as vitamin E, α-lipoic acid and co-enzyme Q10 have all been 
repeatedly shown to have the capacity to inhibit lipid peroxidation and prevent adverse 
downstream effects (34, 35).  Agents that have been demonstrated to effectively neutralize 
and/or remove aldehydes in both experimental models of metabolic and cardiovascular 
diseases as well as clinical studies include taurine (36), histidine analogs (37), and carnosine (38).  
These agents provide a number of different options for stand-alone or supplemental therapy in 
treating diseases where suppression or removal of LPPs is desired.   
Carbonyl stress arising from PUFA peroxidation is known to activate genes involved in 
phase I and II antioxidant/detoxification, mitochondrial biogenesis, and other pathways, all of 
which serve to restrain the further production of PUFA-derived aldehydes and suppress their 
toxic effects. A primary adaptive response pathway that is activated by oxidative and carbonyl 
stress involves NF E2-related factor-2 (Nrf2). Electrophiles such as LPPs and PUFA-derived 
aldehydes generated during periods of oxidative stress activate Nrf2 by liberating it from its 
tethering protein Keap1 in the cytosol, allowing it to translocate to the nucleus where it binds to 
antioxidant/anti-inflammatory response elements (AREs) in promoter regions of genes/proteins 
involved in glutathione synthesis and phase II detoxification (58). Studies have shown that HNE 
induces nuclear accumulation of Nrf2 and up-regulates many GSH-synthesizing enzymes and 
proteins (reviewed in (59)). Indeed, pre-conditioning of the heart by retro-orbital injection of HNE 
induces cardioprotection from ischemia/reperfusion injury via Nrf2, and this cardioprotection is 
lost in Nrf2−/− mice (60). The roles and regulation of Nrf2, and other transcription factors that 




     
 
In addition to Nrf2, recent evidence has implicated members of the peroxisome 
proliferator activated receptor (PPAR) family in the cellular response to ROS. Several reports 
have documented a key role for PPARα and PPARγ in augmenting the antioxidant capacity of 
liver (64-66) and vascular tissue (67, 68)  in response to oxidized PUFAs. Our group recently 
completed a small clinical trial and observed that a concentrated dose of fish oil n-3 PUFA's was 
associated with up-regulation of several antioxidant enzymes, particularly mitochondrial-
localized thioredoxin reductase-2 (TxnRd2), and this was accompanied by increased nuclear 
transactivation of PPARγ, in atrial myocardium of patients undergoing cardiac surgery (69). This 
finding is particularly intriguing given the emerging evidence that TxnRd2 is critical for 
maintaining mitochondrial redox balance in multiple cell types and tissues, including the heart 
(70-72). These articles and other recent literature documenting the beneficial adaptations to 
ROS in striated muscle under various physiological contexts are listed in Table 1. 
Another key adaptive response to ROS includes activation of cellular quality control pathways in 
myocytes, namely autophagy and mitophagy. These pathways are a very active and rapidly 
expanding area of research, and well beyond the scope of this work. The role of 
autophagosome formation in the adaptive response to ROS in myocytes and is the topic of a 
number of thorough reviews (73-75)  
LPP detoxification occurs at two main stages. The first is at the site of lipid peroxidation 
itself (membrane-localized), and the second is in the cytosol. Following their formation, LPPs 
may undergo phase I biotransformation where they are conjugated to antioxidant molecules (i.e., 
glutathione). Alternatively, LPPs are converted by phase II detoxification enzymes such as 
aldehyde dehydrogenase (76), which converts LPPs to their corresponding alcohols. Below we 
discuss some of the major enzymes involves in the detoxification of LPP-derived aldehydes. It is 
important to note for many of these enzymes, their enzymatic efficiency is itself decreased by 




     
 
enzymes responsible for detoxifying LPPs, along with the reaction catalyzed by the enzyme, 
can be viewed in Box 1. 
 
Glutathione peroxidase 4.  
GPX4, which is also known as Phospholipid Hydroperoxidase, is a member of the glutathione 
peroxide family of selenoenzymes enzymes. GPx4 was first identified in 1982 by Ursini et al 
(77). GPX4 prevents the initiation step in free radical attack of the lipid membrane this has been 
demonstrated to occur specifically in the mitochondria (78). Unlike other members of the GPx 
family of enzymes, which are tetramers, GPx4 is a 20-22kDa monomer (79).  
In addition to being able to neutralize small hydroperoxides such as H2O2, it is one of 
only a few enzymes capable of neutralizing complex and bulky hydroperoxides (e.g., cholesterol 
hydroperoxides) (80-83). GPX4 is unique in that unlike other GPXs, it is not limited to 
glutathione as a substrate (83). Its protein thiols can perform the function of GSH, and as a 
result, GPX4 may function as either a glutathione peroxidase or a thiol peroxidase adapting to 
perform its functions depending on cellular redox conditions. The catalysis of GPx4 occurs 
though a tert- ping-pong mechanism (84), which is similar to other members of the GPx4 family. 
The primary studies conducted by Ursini et al. reported that although GPx4 could metabolize 
H2O2 molecules like other members of the family, it did possess a higher affinity for “lipophilic, 
interfacial substrates” compared to other members of the GPx4 family (85, 86). 
There are 3 major isoforms of GPX4: cytosolic, mitochondrial and nuclear (87). GPx4 is 
synthesized as a long form, which contains a peptide, which directs it to the mitochondria and a 
short-form that is present in other cellular compartments such as cytosol, nucleus and 
endoplasmic reticulum. GPx4 activity is has been observed in both the inner and external 
mitochondrial membranes. Many studies have overexpressed GPx4 in vivo in order to elucidate 




     
 
insults presented by lipid peroxide species including phosphotidyl choline, linoleic acid as well 
as inhibitors such as rotenone and cyanide. In the mitochondria, GPX4 over-expression has 
been shown to protect against cytochrome c release, generation of H2O2 and loss of membrane 
potential following ischemia/reperfusion injury (88). In diabetic mice, over expression of 
mitochondrial GPX4 was protective against cardiac ischemia reperfusion injury and preserves 
mitochondrial integrity (89-93). GPx4 is under the regulation of a number of transcription factors 
including Nrf-2,Guanine rich sequence-binding factor 1 (GRSF-1) (94), p-53 and SP-1. 
Disruption of the GPx4 gene in mouse models has been conducted independently by a number 
of different groups. GPx4 is embryonic lethal at E7.5. Tamoxifen induced knockouts are lethal 
within two weeks of treatment (95).  
In addition, to its antioxidant action, GPx4 has been shown to have an important role in 
preventing apoptosis in a variety of models (96). In a study that compares markers of liver 
apoptosis following diquat exposure GPx4 was shown to modulate the release of apoptotic 
proteins from the mitochondria and prevent cardiolipin oxidation (97, 98). Work from Ran et al. 
demonstrates that the cross talk between GPx4 and apoptosis may be complex.  This group 
shown that in GPx4 heterozygote knockouts, although there is greater apoptosis, these mice in 
fact have that have a longer lifespan. (99). GPx4 exerts a significant influence on lipoxygenase 
metabolism (100, 101), which is important in light of the contribution of chronic low-grade 
inflammation to metabolic syndrome. 
 
GPx4 in metabolic disease and aging studies 
ROS are thought to be a major mechanism through which aging occurs therefore it follows that 
GPx4 content and levels important in counteracting aging. According to studies conducted in 
rats the general trend appears to be GPx4 activity is lowest in the tissues of younger animals, 




     
 
instance in the liver, GPx4 activity increased by 25%, in the liver and kidney it remains about the 
same whether as in the heart there is a slight decrease (102). In contrast that of other GPx 
enzymes is almost 2 fold lower in aged compared to adult rats (102). Human studies that 
investigate potential roles of GPx4 in disease are sparse but have grown in number in recent 
years. A single nucleotide polymorphism (SNP) in a small group of 66 patients has 
demonstrated to have an impact on lipoxygenase metabolism (103). GPx4 polymorphisms have 
also been demonstrated to predispose endothelial dysfunction (104). GPx4 is responsive to 
ischemia reperfusion (Beckman 1991). GPX4 levels increase after reperfusion the kidney within 
an hour in response to ischemia. More recently in the context of metabolic syndrome GPx4 
polymorphisms have been associated with obesity in children (105). 
 
Glutathione S-transferase (GST). The GSTs conjugate electrophilic aldehydes with GSH to 
yield a less reactive conjugate that is eliminated from the cell by glutathione S-conjugate efflux 
pumps, this process not only increases the solubility of conjugated compounds but also marks 
these structures for elimination from the cell (106). ROS regulate the expression of GST via c- 
fos and c jun signaling (107). A study in rat hepatocytes reported that for HNE, metabolism by 
GST is responsible for the majority of HNE removal (~60%); a little is metabolized by the alcohol 




Aldehyde dehydrogenase. The ALDHs are particularly relevant in the mitochondria as 
metabolizers of aldehydes generated from PUFAs and monoamine oxidase, as it has been 
demonstrated that inhibiting ALDH activity has a direct impact on the metabolism of amines by 




     
 
mitochondrial isoform (111). In human populations, individuals with a polymorphism for ALDH2 
had higher levels of the biomarker C-reactive protein following myocardial infarction (112). In the 
SAPPHIRe prospective cohort study patients with ALDH2 genetic variants with a possessed 
two-fold greater risk of progression to clinical hypertension (113). ALDH3A2 also was found to 
be important in redox-related pathologies stemming from nutritional overload. It is expressed in 
both the heart and skeletal muscle and displays substrate specificity for aldehydes of various 
long and short chain fatty acids. 
Molybdenum hydroxylases. There are two main enzymes in this class (1) Aldehyde oxidase 
(AOX): This enzyme oxidizes aldehydes to carboxylic acids and it is relatively nonspecific and 
its endogenous role is not well understood. (2) Xanthine Oxidase: exists as xanthine 
dehydrogenase-metabolism of aldehydes by xanthine oxidase generates radicals. These two 
enzymes share some amino acid sequence homology and both contain molybdenum and iron 
as well as Flavin adenine dinucleotide (FAD) as co-factors. 
Carbonyl reductases. Carbonyl reductases are part of short chain dehydrogenases/reductases 
(SDR) family of proteins. These enzymes are ubiquitous and are largely localized to the cytosol 
with some isoforms in the mitochondria and peroxisomes (114). 
Aldo-ketoreductases. The aldose reductases metabolize lipid aldehydes and their glutathione 
conjugates (115). AKR1 specifically metabolizes aldehydes produced by MAO using NADPH. 
The mitochondrial isoform accounts for 5% of cell activity and metabolizes 4-HNE. AKR1B uses 
both NADH and NADPH and is also localized in the cytosolic fraction (116). It is highly 
expressed in the cardiovascular system, appears to be partly responsible for reducing 






     
 
Carbonyl stress, chronic Inflammation and profibrotic signaling in the 
obese/diabetic heart 
Elevated LPPs may in fact be responsible for shifting the dynamic equilibrium in favor for AGE 
formation by increasing the stabilization of the Amadori product thus augmenting profibrotic 
remodeling (117, 118). The most prominent histopathologic finding in the hearts of Type II 
Diabetes patients is fibrosis, as damaged myocardium is infiltrated by fibroblasts (15, 119). 
Myocyte death, collagen deposition and development of fibrotic lesions are visible even before 
decreased cardiac performance is observed (120, 121). Upon initial onset, fibrosis is a 
compensatory response that adds increased tensile strength to counteract pressure overload in 
the heart. The transition to maladaptation occurs gradually as muscle fibers are encased in 
extracellular matrix, leading to ventricular wall stiffening and ultimately decompensation, which 
manifests as diastolic dysfunction (122).  
Over-production of extracellular matrix has physical effects on the microstructure as well 
as changes in physiological environment through the release of factors such as Transforming 
growth factor beta (TGF-β) (123). The most notable change in cellular physiology is the 
transformation of fibroblasts to myofibroblasts.  Myofibroblasts are crucial in the normal 
response to injury and there is evidence to suggest the processes that trigger this 
transformation are tissue dependent (19, 124). Myofibroblasts are highly specialized for the 
secretion of extracellular matrix.  Furthermore, they are more responsive to stimulation by 
factors such cytokines (125).  In certain patients this transition in phenotype to a myofibroblast-
predominant population of cells may increase risk of adverse cardiac events (126, 127). For 
example, as poor transmitters of electric potential this change in phenotype may directly 
account for increased risk of ventricular arrhythmias. Studies show that hyperglycemia/ insulin 
resistance promotes fibroblast - myofibroblasts transformation (19).  Furthermore in the context 




     
 
modified proteins produces a similar phenotype transition (120).  Carbonyl scavengers such as 
carnosine may mitigate this effect and it is postulated that inhibition of the TGF-β pathway may 
serve as a potential mechanism (128). These observations are not confined to patients with 
metabolic syndrome, in fact in a subset of ‘healthy’ obese patients with a relatively normal 
metabolic profile (normotensive, euglycemic), the early stages of irreversible fibrotic cardiac 
remodeling have been observed (129).  
 
Advanced Glycation End-products, a unique type of carbonyl stress with 
therapeutic potential 
The Receptor for Advanced Glycation End-products (RAGE) is a 35KDa receptor that belongs 
to the immunoglobulin G family of receptors (130, 131).  RAGE does not recognize a primary 
amino acid sequence or arrangement. It is essentially a Pattern Recognition Receptor (PRR) 
that displays affinity to a wide variety of glycated proteins (132). Since in many cases lipid 
peroxidation end-products (LPPs) and advanced glycation end products (AGE) often share 
structural homology, proteins modified with LPPs (e.g., HNE, MDA) may serve as candidate 
ligands for RAGE. The importance of RAGE in diabetic pathologies (retinopathy, neuropathy) is 
an established and active area of study. In the context of carbonyl stress RAGE may serve as a 
key mediator of carbonyl stress in cardiometabolic disease. Formation of AGE occurs through 
the Maillard reaction, which is discussed extensively elsewhere. Aldehydes contribute in the 
conversion of the unstable Schiff Base intermediate in an irreversible rearrangement reaction to 
a stable Amadori product (133-135). Therefore in conditions of elevated carbonyl stress, it is 
plausible that increased cross- linking of Amadori products would shift the dynamic equilibrium 
even more in favor of the formation AGE according to Le Chatelier’s principle. This would, in 




     
 
RAGE signaling activates numerous pathways but two are of key interest in relation to 
cardiac remodeling (136, 137). In this context, increased localized RAGE tissue expression and 
activation may serve as a form of localized ‘metabolic memory’ through which previous insults 
are sustained through lingering signals (130). RAGE gene translation is regulated by the nuclear 
factor kappa-light-chain-enhancer of activated B cells (NFκB) transcription factor (130). 
Conversely, NFκB is also activated by RAGE signaling.  The RAGE/ NFκB axis is unique in that 
it typically overwhelms endogenous auto-regulatory feedback inhibition loops. In other words, 
once RAGE switches NFκB on, it is difficult to switch off. Carbonyl stress may contribute to 
chronic low-grade inflammation through this mechanism (138). Chronic low-grade inflammation 
is a mechanism that underlies many diseases associated with metabolic syndrome (139). The 
cyclic pattern of RAGE/ NF-κB activation is consistent with these observations. This may explain 
in part why deterioration of cardiac function persists even after onset of anti-hyperglycemic 
therapy. Interestingly, treatment with the antioxidant selenium, which induces the expression of 
many glutathione-dependent antioxidant enzymes, has been shown to reduce both RAGE 
expression and NF-κB activation in diabetic rats (140).  RAGE is a well-known activator of the 
TGF-β pathway   (133, 139, 141, 142).  The TGF-β proteins are pleiotropic and have been 
implicated in diverse mechanisms, which include cell differentiation and proliferation. TGF-β 
receptors type I and II (TGFβRI and TGFβRII) are present in virtually all mammalian cells TGF-
β1, the major isoform in heart, is expressed in cardiac fibroblasts and cardiac myocytes (CMs) 
and stimulates transformation to myofibroblasts and proliferation, as well as ECM production. 
Active TGF-β1 binds membrane receptors that activate downstream signaling molecules Smad2 
and Smad3, which are phosphorylated on the C-terminal serine residues.  Phosphorylated 
Smad2 and Smad3 (pSmad2 and pSmad3) bind to Smad4 and translocate to the nucleus. The 
Smad complex then binds to response elements in the promoter regions of the ECM genes and 




     
 
abundance of mRNA for collagen types I and III in the whole heart and enhances collagen type I.  
Models of TGFβ1 overexpression in mice suggest that Smad2 is the isoform involved in cardiac 
remodeling involving hypertrophy and fibrosis (139, 141, 142).  In human fibroblasts, HNE 
suppresses the TGF- β medicated production of elastin, which compromises ventricular 
elasticity (144). 
Pharmacological Intervention and Tools 
Relatively few studies have tested compounds that target lipid peroxidation and or neutralize 
LPPs. Viable drug candidates need to be sufficiently lipophilic in order to enter cellular 
compartments, as well as nucleophilic enough for carbonyl species to preferentially react with it, 
or alternatively break the covalent bond formed. It is imperative that the drug is only moderately 
reactive (which would be selectively beneficial in obese/diabetic patients) since many groups 
have demonstrated that ‘over-scavenging’ can potentially interrupt the normal redox cell 
signaling pathways and can be detrimental to health. A brief description of drugs that have been 
explored in this capacity is provided below in Box 1.2 with information pertinent to 
cardiometabolic disease included where available. In addition, other compounds relevant to this 
discussion but not included in this table include Angiotensin converting enzyme inhibitors, AT1 
angiotensin receptor inhibitors, N-acetyl cysteine and antioxidants such as Tocopherol-α and, 
resveratrol (25). 
 
Carnosine and its derivatives 
Carnosine, discovered in 1900, was the first member of the family of histidine containing 
dipeptides identified (145). Carnosine is a β- alanyl-L- histadine dipeptide present in 
extraordinarily high concentrations in skeletal muscle, particularly in white muscle, which can 
contain up to 0.6% wet weight. The heart contains derivatives of carnosine and other members 




     
 
compounds is not well understood. Muscle often possesses a mixture of these compounds 
concentrated around synapses (145) .  
Metabolism: Dietary meat consumption is the largest source of carnosine (147). 
Carnosine uptake in the small intestine occurs through via a proton dependent oligotransporter 
called the HPepT1(148). Carnosine is hydrolyzed by two enzymes, carnosinase which is highly 
specific and homocarnosinase (149). These enzymes are found in the in the plasma, and 
tissues such as the liver and kidney and comparatively low levels in skeletal muscle and this 
may account for the extremely high levels of carnosine in this tissue (145).  Carnosine enters 
muscle tissue only when it is contracting (145). Carnosine possesses a high buffering capacity 
and this points towards its possible role in muscle (145). 
Function: In some muscles carnosine accounts for up to a third of buffering capacity at 
neutral pH (150)  (Davey, 1968). It also chelates metal ions. Carnosine has been shown to 
increase the activity of metabolic enzymes such as glyceraldehydes 3 phosphate 
dehydrogenase. Carnosine increases the activity of the ATPases, Na+ /K+ ATPase and Ca-
ATPase (145). It improves the efficacy of reactions by reducing activation energy and increasing 
coupling of reactions. Interestingly enough these effects are only observed in compromised 
membrane preparations. This brings us to a major functional role of carnosine and this is 
preserving membrane function (151).  Carnosine is known to preserve membrane integrity by 
reducing lipid peroxidation in a concentration dependent manner. These properties of carnosine 
are thought to be linked to the pH by protonation of the imidazole ring in the molecule (145). At 
physiological pH carnosine inhibits the initiation and chain reaction of lipid peroxidation. 
Furthermore it is known that as the lipid membrane is modified the distortion of lipids allows for 
greater penetration of carnosine into the intermembrane space. Carnosine reacts directly with 
ROS such as hydroxyl radical, superoxide anions (147, 152). Carnosine has a synergistic effect 




     
 
levels of carnosine are not changed by training therefore this suggests that there may be 
significant benefit gained from therapeutic administration of this drug since natural means e.g. 
exercise do not affect its levels  (150).  
A significant limitation to the clinical application of carnosine as a therapeutic is that it is 
rapidly hydrolyzed. A number of approaches have been used to circumvent this one of these is 
the use of the D-enantiomer of carnosine, however it has low bioavailability (152) since it’s 
configuration is incompatible with that of the transporters (148). Following these studies d-
carnosine octylester was synthesized to improve bioavailability (154). In the ApoE mouse fed a 
western diet, d-carnosine octylester mitigated atherosclerosis (155). It has also been shown to 
improve dyslipidemia and renal function (156). The development of more potent derivatives is 
currently an active area of research. 
 
Conclusion 
Despite the overwhelming amount of literature available in support of the significant role of LPPs 
in cardiometabolic disease there are few studies that have attempted to elucidate this 
relationship. This dissertation will seek to address this deficiency in the knowledge base using 
high fat high sucrose fed models of elevated (GPx4 mice) and diminished carbonyl stress 
(carnosine derivative treated) mice to test the central hypothesis: LPPs are responsible for 
reduced mitochondrial efficiency and cardiac fibrosis associated with diet induced obesity. Using 
this dual approach we have conducted a series of studies that will serve as a foundation for 
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Figure 1.0 Top:  Primary sites of ROS formation in mitochondria, and reaction scheme for 
peroxidation of cardiolipin in outer- and inner-mitochondrial membrane (51).  Sites of 
ROS formation at Complex I and III are depicted, with the formation of hydroxyl radical (OH●─) 
circled in red.  Electrophilic attack on cardiolipin from OH●─ initiates lipid peroxidation by 
abstracting hydrogen from a methylene carbon in cardiolipin fatty acyl side-chain.  Stepwise 
reaction scheme and products formed are outlined in dashed box.  Dashed box:  The general 
reaction scheme of non-enzymatic lipid peroxidation in mitochondria with initial step coming 
from OH● attack of unsaturated fatty acids contained within cardiolipin (step 1).  Following 
initiation by OH●, an unstable lipid radical is formed, which can continue to abstract allylic 
hydrogens from nearby unsaturated fatty acids (step 2), or react with molecular O2 (step 3) to 
form a lipo-peroxyl radical that either continues on to react with another fatty acid forming a new 










     
 
 
Figure 1. 2.  The major lipid peroxidation product detoxification systems present in the 
mitochondria and cytosol.  (51)  Lipid peroxidation can be blunted directly by GSH removal of 
OH●─ prior to imitation of lipid peroxidation.  GSH is also used by the enzyme glutathione 
peroxidase 4 (GPx4), also known as phospholipid hydroperoxide glutathione peroxidase, to 
neutralize lipid peroxides as they are formed in mitochondrial membrane.  Once aldehydes are 
formed (examples in box), the most physiologically relevant enzyme in neutralizing these 
electrophiles is the aldehyde dehydrogenase (ALDH) family, with ALDH2 and ALDH3a1 as most 
likely candidate enzyme for removal of aldehydes in mitochondrial matrix and cytosol, 
respectively.  Exogenous agents known to suppress lipid peroxidation and/or neutralize 











































Obesity in a model of gpx4 haploinsufficiency uncovers a causal role for lipid-
derived aldehydes in human metabolic disease and cardiomyopathy 
 
As published in: 
Katunga, LA, Gudimella P, Efird JT, Abernathy S, Mattox TA, Beatty C, Darden TM1, Thayne KA, 
Alwair H, Kypson AP, Virag JA, Anderson EJ. Obesity in a model of gpx4 haploinsufficiency 
uncovers a causal role for lipid-derived aldehydes in human metabolic disease and 



















Objective - Lipid peroxides and their reactive aldehyde derivatives (LPPs) have been 
linked to obesity-related pathologies, but whether they have a causal role has remained 
unclear.  Glutathione peroxidase 4 (GPx4) is a selenoenzyme that selectively neutralizes 
lipid hydroperoxides, and human gpx4 gene variants have been associated with obesity 
and cardiovascular disease in epidemiological studies.  This study tested the hypothesis 
that LPPs underlie cardio-metabolic derangements in obesity using a high fat, high 
sucrose (HFHS) diet in gpx4 haploinsufficient mice (GPx4+/-) and in samples of human 
myocardium.  
Methods Wild-type (WT) and GPx4+/- mice were fed either a standard chow (CNTL) or 
HFHS diet for 24 weeks, with metabolic and cardiovascular parameters measured 
throughout.  Biochemical and immuno-histological analysis was performed in heart and 
liver at termination of study, and mitochondrial function was analyzed in heart.  
Biochemical analysis was also performed on samples of human atrial myocardium from a 
cohort of 103 patients undergoing elective heart surgery.   
Results Following HFHS diet, WT mice displayed moderate increases in 4-
hydroxynonenal (HNE)-adducts and carbonyl stress, and a 1.5-fold increase in GPx4 
enzyme in both liver and heart, while gpx4 haploinsufficient (GPx4+/-) mice had markedly 
greater carbonyl stress in these organs accompanied by exacerbated glucose intolerance, 
dyslipidemia, and liver steatosis.  Although normotensive, cardiac hypertrophy was 
evident with obesity, and cardiac fibrosis more pronounced in obese GPx4+/- mice.  
Mitochondrial dysfunction manifesting as decreased fat oxidation capacity and increased 
reactive oxygen species was also present in obese GPx4+/- but not WT hearts, along with 





hyperglycemia exhibited significantly less GPx4 enzyme and greater HNE-adducts in 
their hearts, compared with age-matched non-diabetic patients.   
Conclusion These findings suggest LPPs are key factors underlying cardio-metabolic 










PUFA   Polyunsaturated fatty acids 
LPPs  Lipid peroxidation end products 
GPx4  Glutathione peroxidase 4 
HFHS  High fat, high sucrose 
WT  Wild type 
CNTL  Control 
BMI  Body mass index  
4-HNE 4-Hydroxynonenal 
ROS  Reactive oxygen species 
RNS  Reactive nitrogen species 
HDL  High-density lipoprotein 
TG  Triglycerides 
EF  Ejection fraction 
FS  Fractional shortening 
Nrf2  Nuclear factor (erythroid-derived 2)-like 2 
IL-1β  Interleukin-1 beta 
IL-6  Interleukin-6 
TNF-α  Tumor necrosis factor- α  
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1.  INTRODUCTION 
The prevalence of obesity is rapidly spreading throughout the world with over 28% of adults 
having a body mass index (BMI) of ≥25kg/m2 ((1, 2)).  In addition to the increased risk for type 2 
diabetes, a growing number of studies have reported a high prevalence of cardiomyopathy in 
obese patients (~40% by some estimates) ((18)), with ‘preclinical’ myocardial damage ((157)) 
and diastolic dysfunction already evident in young adult (≤ 35yrs) obese/diabetic patients ((158)) 
and even children ((159)).  Importantly, these cardiac derangements appear in the absence of 
detectable coronary disease or hypertension.  Together, these findings strongly indicate a need 
for more careful examination of potential mechanisms that underlie cardiomyopathy in obese 
individuals.   
Polyunsaturated fatty acids (PUFAs) are continuously oxidized in vivo through both 
enzymatic and non-enzymatic reactions ((160, 161)), forming lipid peroxidation end products 
(LPPs) such as isoprostanes, isofurans, thromboxanes, and α, β-unsaturated aldehydes ((162)), 
all of which have biological effects ((163-166)).  These aldehydes cause post-translational 
modifications of proteins through Michael addition with lysines and histidines, and through 
covalent modification of sulfhydryl groups (e.g., cysteines) to form carbonyl adducts ((167, 168)).  
Due to this high degree of reactivity, many of these aldehydes have been proposed to be 
etiologic agents in disease ((160, 169) (57, 167, 169-173)).  4-hydroxynonenal (HNE) is a α, β-
unsaturated aldehyde derived from n-6 PUFA peroxidation, and HNE levels increase 
proportionally with ROS/RNS levels ((47)).  One recent report showed that HNE-modified 
albumin is significantly increased in the serum of type 2 diabetic patients ((174)).   
Mitochondrial membranes are abundant with unsaturated fatty acids, which are prone to 
peroxidation ((54-56)).  The mitochondrion is also the primary source of cellular ROS, making it a 
major source of LPPs ((51)).  As a countermeasure, mitochondria contain an elaborate system of 
antioxidant and LPP-detoxifying enzymes.  One of these is glutathione peroxidase 4 (GPx4), 





specifically scavenge lipid hydroperoxides ((80, 83, 88)).  GPx4 is one of a few antioxidant 
enzymes known to neutralize both simple and complex lipid hydroperoxides (e.g., Cholesterol 
hydroperoxide) ((175, 176)).  It is the only member of the GPx super-family that is indispensable 
during development, with embryonic lethality of GPx4 null mice occurring at stage E7.5 ((177-
179)).  In recent genetic and epidemiological studies, variants of gpx4 that result in diminished 
content and/or catalytic activity have been associated with obesity ((105)), cardiovascular 
disease ((104, 180)) and inflammation ((181, 182)).  However, no experimental studies to date 
have explored GPx4 in the context of obesity or its related pathologies, and this may be a 
significant oversight given the well-known association between mitochondrial-derived oxidative 
stress and metabolic disease ((24, 183)).  In this study, we tested the hypothesis that LPPs are a 
causal factor underlying cardio-metabolic derangements in obesity by investigating the effect of a 
long-term high fat, high sucrose (HFHS) diet in a mouse model of gpx4 haploinsufficiency 
(GPx4+/-) and in samples of human atrial myocardium obtained from non-diabetic and diabetic 
patients undergoing elective heart surgery.   
 
2.  METHODS 
2.1.  Mouse Model and Study Design. Animal care and experimental procedures were 
performed with approval from the Institutional Animal Care and Use Committee of East 
Carolina University and were in compliance with the National Institutes of Health’s Guide for 
Care and Use of Laboratory Animals. C57BL6/J female mice (Jackson Laboratory) were 
crossed to male GPx4+/- mice and pups were genotyped by polymerase chain reaction (PCR) 
using primers described in ((82)). At 8-12 weeks, WT and GPx4+/- male and female age-
matched littermates (n=6) were randomly assigned to groups and individually housed. Mice 
were fed either control (CNTL-TD110367) or high fat high sucrose (HFHS-TD110365) diet from 
Harlan-Teklad Laboratories (Madison, WI) ad libidum for 25 weeks. The composition of this 





with high sucrose (34% kcal/g) content ((72)).  Mice were housed at controlled temperature 
and a 12hr light/dark cycle was maintained.  At the end of the diet period, all live animal 
metabolic and echocardiographic measurements were made 1-2 weeks prior to tissue 
collection to allow for a ‘wash-out period’ to minimize artifact attributable to additional stress 
that may have been introduced by these procedures. 
2.2.  Patient enrollment and myocardial tissue collection.  The Institutional Review Board 
of the Brody School of Medicine at East Carolina University approved all aspects of this study.  
Adult patients undergoing primary, non-emergent elective coronary artery bypass graft (CABG) 
or CABG/valve surgery between January 2011 and December 2014 were enrolled for this 
study.  Demographic and clinical variables for these patients, including preoperative 
cardiovascular and metabolic drugs, are listed in Table 2 according to diabetes status.   Those 
having prior cardiac surgery, history of arrhythmia, or severely enlarged atria (>4.0 cm) were 
excluded from the study.  Atrial appendage biopsies were obtained from each patient as 
previously described ((224)), directly prior to institution of cardiopulmonary bypass.  
Myocardium was dissected from the endocardial side of the biopsy, rinsed briefly and frozen in 
liquid N2.  All samples were rapidly processed this way to minimize protein and mRNA 
degradation across patients. 
2.3.  Metabolic Parameters. Body weight of the mice was recorded on a weekly basis 
throughout HFHS diet.  Body composition was analyzed by nuclear-MRI (EchoMRI 700 Echo 
Medical Systems, Houston, TX).  An oral glucose tolerance test (dose-0.5g/kg) was performed 
following a ~4 hour fast in week 22 of the HFHS diet period.  Glucose levels were measured 
using a standard glucometer (OneTouch UltraMini, LifeScan, Milpitas, CA) in blood collected 
from a tail nick. Serum cholesterol, high-density lipoprotein (HDL), and triglycerides (TG) were 






2.4.  Assessment of Cardiovascular Function.  At end of the diet intervention, blood 
pressure was determined by non-invasive tail-cuff plethysmography (SC1000, Hattaras 
Instruments, Cary, NC).  Mice were acclimated to the procedure for 3 days, and the average of 
blood pressure readings made over 3 consecutive days was recorded.  A single recording was 
an average of 10 measurements after 5 acclimatization cycles, with duration no longer than 10 
minutes, at approximately the same time every day.  Also at this time, high-resolution 
echocardiography was performed on fully conscious mice using a 30 MHz transducer (Vevo 
2100, VisualSonics, Toronto, ON) to assess cardiac function and structural parameters in vivo. 
Parasternal long- and short-axis views were captured in M-mode and recordings analyzed 
using system software. 
 
2.5.  Liver and Cardiac Histology:  Mice were anesthetized with isoflurane. Hearts 
(n=2/group) were stopped with KCl, fixed in Zinc Fixative then embedded in paraffin.  Next, 
they were cut cross-sectionally, stained in Hematoxylin and eosin or picosirus red (collagen), 
then viewed under polarized light. Livers from these animals were fixed, embedded and 
stained in a similar fashion, with the exception that oil red O was used for liver triglycerides. 
Images of each heart were captured at 20X. The cardiomyocyte diameter of 8-10 myocytes 
from 5 captured images per animal was analyzed using Image J (http://imagej.nih.gov/ij/) by an 
individual blinded to the treatment group.  
 
2.6.  Preparation of permeabilized cardiac myofibers and mitochondrial function 
measurements.  All procedures for these measurements have been described in detail by our 
group previously ((22-24, 72)).  The mice were anesthetized with isoflurane and rapidly 
euthanized by pneumothorax.  Blood was collected for serum analysis via cardiac puncture.  
Whole hearts were dissected, weighed, and a small portion of the left ventricle (LV) was cut for 





7.23 K2EGTA, 2.77 CaK2EGTA, 20 Imidazole, 20 Taurine, 5.7 ATP, 14.3 Phosphocreatine, 
6.56 MgCl2-6H2O and 50 MES (pH 7.1, 295 mOsm).  Of the remaining LV/septum, one portion 
was used for standard mitochondrial isolation, and another was snap frozen in liquid N2 and 
stored at -80°C for further biochemical analysis.  Following permeabilization in 50 g/ml 
saponin for 30 minutes, fibers were transferred to Buffer Z containing (in mM): 110 K-MES, 35 
KCl, 1 EGTA, 5 K2HPO2, 3 MgCl2-6H2O, and 5 mg/ml BSA (pH 7.4, 295 mOsm) and remained 
in Buffer Z with 20uM Blebbstatin on a rotator at 4C until analysis (<1.5 hours).  Fibers were 
then transferred to an Oroboros O2K (Oroboros Instruments, Innsbruck, Austria) where 
respiration was recorded in Buffer Z + 20uM Blebbistatin, 20 mM Creatine at 30°C.  Respiration 
(JO2) measurements were performed following addition of 125uM palmitoyl-carnitine + 1mM 
malate followed by 4mM ADP.  H2O2 emission was measured using a spectrofluorometer 
(Photon Technology Instruments, Birmingham, NJ) in Buffer Z + 20uM Blebbistatin, 10µM 
Amplex Red, 1 U/ml horseradish peroxidase, 25 U/ml superoxide dismutase.  For H2O2 
measurements, respiratory substrates used were 125 palmitoyl-carnitine, 2mM Malate + 100 
µM ADP, 5 mM glucose and 1 U/ml hexokinase (i.e., phosphorylating state) followed by 
sequential addition of 5mM glutamate then 5mM succinate. Once mitochondrial experiments 
completed, fibers were collected, rinsed in ddH2O to remove excess salts, and lyophilized 
(Labconco, Kansas City, MO). Fibers were then weighted on a microbalance (Mettler Toledo, 
Denver, CO) and mitochondrial JO2 (oxygen consumption rate) and JH2O2 (peroxide emission 
rate) were normalized to dry weight. 
2.7.  Real-time qPCR of gene expression. Cardiac samples (~10mg) were homogenized in 
glass grinders (Kimble Chase, Vineland, NJ) then subjected to Proteinase K digestion.  All 
materials used in RNA extraction were provided in RNeasy® Fibrous Tissue Mini Kit (Qiagen Inc, 
Valencia, CA cat# 74704).  Reverse Transcription was performed using the iScript ™ cDNA Kit 





reaction cocktail was used in the amplification and detection of DNA in RT-PCR.  All protocols 
were performed according to product specifications unless otherwise stated. Cycle threshold 
(C(t)) values were converted to relative gene expression levels using the 2-ΔΔC(t) method and 
normalized to the level of 18S ribosomal RNA.  Data are reported as fold-change in gene 
expression (arbitrary units) ± S.E.M. relative to WT-CNTL mice (n=4-5 per group). The 
sequences and references for the primers used in qRT-PCR are listed in Supplemental Table 1. 
 
2.8.  Mitochondria Isolation.  The technique applied has been modified from methods 
previously described ((225, 226)).  Briefly, ~100 mg of cardiac tissue was excised and added to a 
petri dish with ice. The tissue was minced for 4-5 minutes, until it could pass through a pipette, 
and subjected to a brief (2 minutes) trypsin incubation.  The mixture was transferred to a 50mL 
conical tube and allowed to settle. The supernatant was removed and discarded. The remaining 
mixture was resuspended in 3mL of Mitochondria Isolation Medium (MIM) (300mM Sucrose, 
10mM Na-HEPES, 0.2mM EDTA) with BSA, then transferred to a pre-chilled Dounce 
homogenizer and slowly homogenized for a total of ~10-12 counts. The homogenate was then 
subjected to a series of differential centrifugation steps. The fractions of isolated mitochondria 
obtained (mixed subsarcolemmal and intermyofibrillar) were resuspended in a small volume of 
MIM+BSA and frozen at -80° for biochemical analysis. 
2.9.  Immunoblot and enzyme-linked immunosorbent assay (ELISA). Cardiac tissue was 
homogenized in TEE-T Buffer (10 mM Tris, 1 mM EDTA, 1 mM EGTA + 0.5% Triton X-100), and 
then loaded on 4-20% pre-cast polyacrylamide SDS gel (Biorad, Hercules, CA) under reducing 
conditions.  Protein was transferred to PVDF membranes (Millipore, Bellerica, CA) and incubated 
with primary antibodies for GPx4 and α-tubulin (Abcam, Cambridge, UK), COX IV and β-actin 
(Cell Signaling Technology, Danvers MA), and HNE-adduct (Percipio Biosciences).  Membranes 
were incubated using infrared fluorophore-conjugated secondary antibodies (LiCor Biosciences, 





densitometry using Image J (NIH).  The absolute quantities of GPx4 and HNE-modified protein 
adducts in human cardiac tissue was determined by a quantitative ELISA approach developed in 
our lab, as described previously ((72)).  Fixed concentrations of HNE-adducts were made by 
incubating 4-hydroxynonenal (Cayman Chemical, Ann Arbor, MI) with BSA.  A standard curve of 
both recombinant GPx4 (AbFrontier, Seoul, Korea) and HNE-modified BSA were then incubated 
on immunolon-coated 96-well assay plate (Fisher Scientific) along with diluted cardiac protein.  
Samples were incubated overnight at 4°C, and subsequently washed with PBS+0.05% Tween-
20 and blocked for 2 hours with BSA or NB4025 (NOF America, White Plains, NY) at 37°C.  
Samples were then incubated with primary antibodies for GPx4 and HNE adduct for 2 hours at 
37°C.  Samples were washed with PBS+0.05% Tween-20 and incubated with HRP-conjugated 
secondary antibody for 2 hours at 27°C.  Following this incubation, samples were washed as 
before and incubated with Amplex Red (10 µM).  Concentrations of GPx4 and HNE-adducts in 
the samples were determined by fitting to the standard curve within each plate and normalized to 
total protein concentration. 
2.10.  Hydrazide labeling of carbonyl-modified proteins: Hydrazide Cy5.5 dye (GE 
Healthcare Bio-Sciences, Pittsburgh, PA) was diluted in dimethyl sulfoxide (DMSO) at a stock 
concentration 1mg/ml. Tissue was homogenized under an anaerobic chamber (Coy Laboratory 
Products, Grass Lake, MI) in 10mM sodium phosphate buffer, containing 0.1% Triton X-100, and 
de-gassed using dry vacuum pump (Welch No. 25228-01, Monroe, LA).  Dye was added to half 
of the homogenate (1:10). The samples were left under anaerobic conditions for 2 hours and 
incubated overnight on orbital shaker at 4C. The other aliquot of tissue homogenate was used to 
quantify protein content. Portions of the labeled cardiac tissue homogenate were subjected to 
SDS-PAGE on 10% SDS polyacrylamide gel.  The gels were scanned using Odyssey Clx 
Infrared Imaging System (Li-Cor) and Cy5.5-labeled proteins were analyzed by densitometry 





2.11.  Statistical Analysis.  All animal data are presented as mean ± SEM. Statistical analysis 
on mouse model variables were performed with Graph Pad Prism (Graph Pad Prism, La Jolla, 
Ca.).  One-way ANOVA was performed on continuous variables followed by Newman-Keuls 
posttest, with α< 0.05 considered statistically significant.  In the human data analysis, categorical 
variables are presented as frequency and percentage and continuous variables were presented 
as mean ± standard deviation, mediation, median and interquartile range.   Fisher exact and Chi 
(χ2) procedures were used to compute statistical significance of group comparisons for 
categorical variables.  Deuchler-Wilcoxon was used for continuous variables.  Biochemical 
variables were divided into quartiles (GPx4) or tertiles (HNE) and analyzed using a robust 
Poisson regression model (with relative risk as the measure of association).  Missing values for 
all clinical and biochemical variable were imputed using the iterative expectation-maximization 
(EM) algorithm as described in a recent study ((224)).  Variables that were statistically significant 
in the univariable analysis were included into the multivariable analysis.  P-value was computed 
using Friedman’s Nonparametric test for central tendency while adjusting for age.  Ptrend was 
computed using likelihood ratio trend test, adjusting for age and sex.  Statistical significance was 
defined as P<0.05. SAS Version 9.3 was used for all analyses of human biochemical and clinical 
variables. 
 
3.  RESULTS 
3.1.  GPx4 deficiency in obesity leads to enhanced lipid peroxidation and carbonyl stress 
in liver, exacerbating insulin resistance and steatosis.   
To test our hypothesis that LPPs underlie obesity-related pathologies we used a GPx4-deficient 
(GPx4+/-) mouse model.  GPx4+/- mice are phenotypically indistinguishable from WT in the 
absence of an exogenous stressor but more susceptible to damage from radiation and 





the effect of previously identified gpx4 gene variants on GPx4 enzyme levels and activity in 
human cells ((104, 105, 184)).  Following HFHS diet no significant differences in adiposity or 
weight gain were observed between WT and GPx4+/- mice, although obese GPx4+/- mice had 
substantial dyslipidemia and fasting hyperglycemia with HFHS diet (Table 1).  Whole body 
energy expenditure, determined by VO2 and VCO2 using indirect calorimetry, was not different 
between WT and GPx4+/- mice, either with CNTL or HFHS diet (data not shown).  Glucose 
intolerance was also exacerbated in the GPx4+/- mice compared with WT (Figure 1A), and serum 
insulin levels were also significantly increased with HFHS diet (Figure 1B).  GPx4 enzyme levels 
in liver of WT mice increased significantly as a result of HFHS diet, although GPx4+/- mice 
contain significantly less enzyme than WT (Figure 1C and Supplemental Figure 1A).  In parallel 
with the increase in GPx4, levels of HNE-adducts in liver increased in WT with HFHS diet but 
were significantly more pronounced in GPx4+/- mice compared with WT.  To determine whether 
the increased lipid peroxidation in the GPx4+/- mice corresponded to a more severe liver 
pathology following HFHS diet, liver triglycerides and collagen were measured by oil red O and 
picrosirius red staining, respectively.  GPx4+/- mice displayed markedly greater liver steatosis 
(Figure 1D) and fibrosis (Figures 1E) than WT mice following HFHS diet.   
 
3.2.  Cardiac structural remodeling and fibrosis is exacerbated by GPx4 deficiency in 
obesity.   
Previous studies have shown that HFHS diet-induced obesity causes significant cardiac 
hypertrophy and left ventricular (LV) diastolic dysfunction in rodent models ((185-187)).  Here, 
HFHS diet caused an increase in cardiac mass to a similar extent between WT and GPx4+/- mice 
(Figure 2A, E).  However, compared with WT, GPx4+/- mice display significantly greater 
cardiomyocyte diameter (Figure 2E, F) and fibrosis (Figure 2B, C) following HFHS diet.  Obese 
mice also have increased levels of serum brain natriuretic peptide (BNP, Figure 2G), indicative of 





LV systolic function (Figure 2H), blood pressure (Figure 2I) or heart rate (Figure 2J) in the mice 
following HFHS diet, indicating that any cardiomyopathy which might be present in these mice is 
not due to increased afterload.   
Recently, in two independent experimental models of cardiac hypertrophy it was observed that 
GPx4 and Thioredoxin Reductase (TxnRd) were the only antioxidant seleno-enzymes to 
increase in the heart, suggesting that they are critical for cardiac compensatory response to 
hypertrophic stimuli ((50, 188)).  A significant increase in GPx4 mRNA (Figure 3A) and enzyme 
content (Figure 3B and Supplemental Figure 1B) in myocardium of WT mice with HFHS diet was 
observed.  Conversely, GPx4+/- mice had lower levels of mRNA that did not correspond to any 
changes in GPx4 enzyme levels following HFHS diet.  Levels of HNE-adducts (Figure 3C) and 
protein carbonyls (Figure 3C) do increase moderately in WT hearts with HFHS diet, although 
GPx4 deficiency leads to a striking increase in this protein carbonylation with obesity.  To 
determine if GPx4 deficiency and augmented carbonyl stress in obesity triggered a 
compensatory redox adaptive response in the heart, expression of a number of antioxidant 
genes were examined. GPx4+/- mice were found to have increased expression of several 
antioxidant genes following HFHS diet (Figure 3D).   
 
3.3.  GPx4 deficiency causes mitochondrial abnormalities and up-regulation of cardiac 
inflammation and fibrosis signaling pathways with obesity.   
Mitochondrial dysfunction, as characterized by decreased ATP and/or respiration combined with 
increased ROS, has been linked to several obesity-related pathologies, including insulin 
resistance and cardiomyopathy, and recent studies have implicated a role for mitochondrial 
protein carbonylation in mediating this dysfunction ((189-191)).  Parameters of mitochondrial 
function in permeabilized LV myofibers were examined to assess the interrelationship between 
GPx4 deficiency, carbonyl stress, and mitochondria in the obese myocardium.  Mitochondrial 





GPx4 increased in cardiac mitochondria of WT mice with HFHS diet, while total levels of GPx4 
were lower and remained that way following HFHS diet in the GPx4+/- mice (Figure 4A and 
Supplemental Figure 2A).   
It was expected that mitochondrial GPx4 deficiency would potentially lead to a greater 
degree of mitochondrial membrane lipid peroxidation and reactive aldehyde formation.  Here, the 
amount of mitochondrial HNE-adducts were greater in GPx4+/- hearts than WT, and the HFHS 
diet increased the relative amount of these adducts in both WT and GPx4+/- mice (Figure 4B and 
Supplemental Figure 2B).  These increased HNE-adducts may have functional consequences 
since recent studies have documented that mitochondrial HNE-adducts correspond to decreased 
oxidative phosphorylation in diabetic heart mitochondria ((192, 193)).   Moreover, another report 
highlights the importance of mitochondrial fatty acid β-oxidation as a metabolic ‘sink’ for HNE 
((194)).  In WT hearts, both basal and maximal ADP-stimulated Palmitoyl-L-carnitine supported 
respiration was markedly increased following HFHS diet, while these rates were unchanged with 
HFHS diet in the GPx4+/- mice (Figure 4B).   
In a previous study we reported that the selenoenzyme thioredoxin reductase-2 (TxnRd2) 
increased in rat heart with HFHS diet ((72)), corresponding to a decreased rate of mitochondrial 
H2O2 emission in the obese rat heart.  Other groups have also reported decreased mitochondrial 
ROS with obesity/diabetes in mouse ((195)) and rat models ((196)).  Given our previous findings, 
combined with the fact that TxnRd2 expression was increased in GPx4+/- hearts with HFHS diet 
(Figure 3E), we sought to ascertain whether a similar adaptation in redox buffering was occurring 
in cardiac mitochondria of these mice.  Here, using paired H2O2 emission experiments in the 
absence and presence of the TxnRd2 inhibitor auranofin, a dramatic (~4-fold) increase in total 
H2O2 emission was observed in permeabilized myofibers prepared from obese GPx4+/- mice fed 
HFHS diet, while a decrease in this ROS emission was observed in the obese WT mice following 
HFHS diet (Figure 4C).  Auranofin exposure significantly increased the rate of mitochondrial 





Chronic, low-grade inflammation in the obese heart is known to cause profibrotic and 
hypertrophic signaling.  Although it has been difficult to fully ascertain the exact nature of the 
relationship between inflammation and cardiac remodeling, some investigators have proposed 
that activation of the receptor for advanced glycation end products (RAGE) may play a role.  
RAGE belongs to a family of pattern recognition receptors for AGE and has been studied 
extensively in the context of diabetes-related pathologies ((132, 197)).  Increased expression of 
RAGE is present in the hearts of obese GPx4+/- mice (Figure 5A), and this is consistent with the 
increased carbonyl stress present in these hearts since reactive aldehydes such as HNE are 
known to potentiate AGE formation ((198)).  Activation of RAGE has been shown to induce 
chronic activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), which, 
in turn, activates further inflammatory pathways.  Furthermore, there is extensive crosstalk 
between the RAGE and Transforming Growth Factor-Beta (TGF-β) family of proteins ((123, 141, 
199)).  Notably, the hearts of obese GPx4+/- mice also displayed greater pro-inflammatory 
cytokine expression and genes involved in fibrosis and hypertrophy compared with WT following 
HFHS diet, while only a modest increase in a few select genes was observed with HFHS diet in 
WT hearts (Figure 5A & B). 
 
3.4.  Cardiac GPx4 deficiency is associated with increased HNE-adducts and relative risk 
(RR) for diabetes in humans.  Next, we sought to determine whether there is an association 
between GPx4 and lipid-derived carbonyl stress in human heart and, also, to examine whether 
there is a connection between these parameters and human metabolic disease.  In a small pilot 
study of ~20 patients, we previously reported greater levels of HNE-protein adducts in the hearts 
of hyperglycemic type 2 diabetic patients, and these increased HNE-adducts were accompanied 
by depletion of cardiac glutathione and increased mitochondrial ROS production ((200)).  Here, 
using samples of atrial myocardium obtained from patients (n=103) undergoing elective cardiac 





non-diabetic patients (Figure 6A), and this corresponded with greater levels of HNE-adducts in 
the diabetic hearts (Figure 6B).  A multivariable regression analysis was performed on quartiles 
of cardiac GPx4 and tertiles of HNE-adducts, and cardiac GPx4 was found to be negatively 
associated while HNE-adducts positively associated with RR for diabetes in these patients 
(Table 3).  To determine if hyperglycemia was associated with cardiac GPx4 or HNE-adducts in 
these patients, a multiple linear regression model was applied, adjusting for sex.  No significant 
association between cardiac GPx4 or HNE-adduct levels and HbA1c was observed in these 
patients (Table 3 and Supplemental Figure 1). 
Similar to what was observed with the WT-HFHS mice, cardiac GPx4 content was 
positively correlated with cardiac HNE-adducts in these patients (Figure 6C), suggesting that 
GPx4 is an adaptive response of the tissue to persistent oxidative stress.  Interestingly, the ratio 
of HNE-adducts/GPx4 was much higher in diabetic than non-diabetic hearts (Figure 6D), 
indicating that the GPx4 adaptive response has been over-whelmed or compromised in these 
patients.   
 
4.  DISCUSSION 
Only an increased understanding of the mechanisms underlying obesity-related pathologies will 
enable physicians to better manage diseases associated with this emerging epidemic.  Lipid 
peroxides and their reactive aldehyde derivatives have been postulated to play a causal role in 
obesity-related cardio-metabolic diseases, and emerging epidemiologic data has reported a link 
between polymorphisms and mutations in gpx4 and human diseases, including obesity. Together, 
these previous findings suggest that GPx4 may be an adaptive component that serves a 
protective role against the persistent oxidative stress in obesity.  The present study tested this 
hypothesis in a translational model of HFHS diet-induced obese GPx4+/- (i.e. GPx4 deficient) 
mice, combined with cardiac tissue samples obtained from patients undergoing elective cardiac 





leads to significant increases in lipid peroxide-derived aldehydes, corresponding to more severe 
cardio-metabolic derangements including glucose intolerance, dyslipidemia, liver steatosis, and 
cardiac hypertrophy and fibrosis.  Abnormalities in mitochondrial function in hearts from the 
obese GPx4+/- mice implicate a role for the enzyme in protecting that critical organelle from 
oxidative damage in obesity.  Furthermore, the adverse cardiac remodeling observed in the 
obese GPx4+/- mice was accompanied by up-regulation of genes involved in cardiac 
inflammation and remodeling, illustrating the importance of carbonyl stress as a causal factor in 
these pathways.  Lastly, the relationship between decreased cardiac GPx4 and increased HNE-
adducts and human metabolic disease was confirmed by studying cardiac tissue samples 
obtained from non-diabetic and diabetic patients.  Collectively, these observations allow for a 
proposed model of GPx4 as a protective adaptation in obesity (as shown in the Graphical 
Abstract).  Clearly, when HNE-adducts increase as a result of persistent lipid peroxidation in 
obesity/nutrient overload, GPx4 becomes upregulated to compensate (Figure 1 & 3).  However, 
over time and possibly due to underlying genetic causes, GPx4 becomes overwhelmed in an 
obese individual and HNE-adducts increase.  The consequence of this is increased inflammation, 
mitochondrial dysfunction (and likely potentiation of mitochondrial ROS), and the broad cardio-
metabolic pathologies that are known to follow (e.g., diabetes, cardiomyopathy, liver disease). 
These findings stand in contrast to preceding studies of diet-induced obesity in 
antioxidant-deficient models.  One recent study of high fat-fed GPx1-deficient mice (whole body 
GPx1-/-) found that systemic oxidative stress increased with obesity as expected, but these mice 
were actually protected from insulin resistance and liver steatosis (99).  In a study using high fat 
diet in SOD2+/- mice (also exhibiting greater oxidative stress), insulin sensitivity was again 
unchanged with obesity, although a modest effect on pancreatic β-cell release of insulin was 
observed (100).  Another intriguing study used high fat diet in a glutathione-deficient (Gclm-/-) 
mouse model.  The authors found that despite a huge increase in systemic oxidative stress with 





steatosis, possibly due to an increase in basal energy expenditure (101).  Given these recent 
findings, the fact that GPx4 haploinsufficiency alone can induce such a dramatic effect on cardio-
metabolic disease parameters with HFHS diet implies that lipid peroxides must play a very 
prominent etiological role in obesity-related cardio-metabolic diseases. 
Deleterious effects of lipid-derived aldehydes in biological systems have been well known 
for many years.  For example, nucleophilic attack of cysteine residues by aldehydes has 
negative ramifications on metabolic pathways in the cell ((167, 201)).  A recent mass 
spectrometric analysis of cysteine oxidation status in hearts from mice fed a diabetogenic diet for 
8 months showed that ~40% of total oxidized cysteines are mitochondrial in origin ((202)).  
Proteomic analysis of mitochondria from diabetic rat hearts reveals an increased formation of 
carbonyl adducts (e.g. HNE, MDA) with complexes of the electron transport chain and respiratory 
complexes, and these adducts correspond to a reduction in enzyme activity ((170)).  Our data 
suggest that GPx4 protects against cardiac mitochondrial dysfunction with obesity as the obese 
GPx4+/- mice had very high levels of carbonyl stress in their hearts (Figure 3), particularly HNE-
adducts in the cardiac mitochondria (Figure 4B), accompanied by mitochondrial dysfunction, as 
compared with obese WT mice.  Several studies have shown that GPx4 preserves ATP 
production and attenuates cytochrome c release in the mitochondria under oxidative stress 
((203-205)).  Cardiac-specific overexpression of mitochondrial GPx4 is protective in models of 
cardiac ischemia/reperfusion injury and in a streptozotocin (STZ)-induced diabetes model ((92, 
206)).  GPx4 exists as both short (i.e., mitochondrial-localized) and long (i.e., cytosolic-localized) 
isoforms, yet only deletion of the former is lethal in mice ((207)).  Thioredoxin Reductase is the 
only other essential selenoenzyme identified to date, and this enzyme also has both 
mitochondrial (TxnRd2) and cytosolic (TxnRd1) isoforms ((208)).  In the present study, increased 
mitochondrial H2O2 emission was observed in hearts of lean GPx4+/- mice following the inhibition 
of TxnRd2 with auranofin (Figure 4C), although auranofin did not significantly affect the rate in 





that mitochondrial lipid peroxide-scavenging with GPx4 and the thioredoxin redox couple are 
both important adaptive responses of cardiac mitochondria in obesity-related cardiac hypertrophy 
and that TxnRd2 cannot appropriately compensate for GPx4 deficiency within cardiac 
mitochondria if animals are obese. 
A recent study showed that fatty acid β-oxidation is a novel HNE clearance pathway in 
heart (194)).  Considering the diminished rates of maximal Palmitoyl carnitine-supported 
respiration observed in the obese GPx4+/- hearts, it is plausible that the elevated carbonyl stress 
observed in the hearts of these mice is a result of both increased mitochondrial ROS production 
(which initiates more lipid peroxidation) as well as a disruption of aldehyde detoxification 
pathways.  The decreased GPx4 and correspondingly increased HNE-adducts seen here in 
myocardium of diabetic patients support our previous observations of decreased Palmitoyl-L-
carnitine supported respiration and increased mitochondrial ROS in diabetic human hearts ((23, 
24)).  A link between mitochondrial HNE-adduct formation and decreased oxidative 
phosphorylation in diabetic heart mitochondria has recently been made ((192, 193)), and our 
findings suggest that GPx4 deficiency may underlie these oxidative modifications.  High 
variability in dietary fat may also be a contributor to the greater levels of cardiac HNE-adducts in 
the diabetic patients, as it has been reported that diets consisting of high fat mixed with 
carbohydrate, or high fat alone, can lead to drastically different outcomes in HNE accumulation in 
oxidative tissues (102).  Other studies directed at examining the role that alternative aldehyde-
producing (e.g., monoamine oxidase) and detoxifying enzymes (e.g., aldehyde dehydrogenases) 
may have in pathologies of obese/diabetic hearts may also be useful ((201)).  In addition, an 
improved understanding of the regulation of selenocysteine status may serve as a major clue to 
uncovering the mechanisms that govern the progression to maladaptive remodeling in hearts of 
patients with metabolic disease.  Epidemiological studies of Keshan’s disease, a cardiomyopathy 
endemic to regions of China, confirm that the heart is highly susceptible to injury resulting from 





acute cardiac fibrosis and mitochondrial dysfunction ((209)), a phenotype that is strikingly similar 
to the GPx4+/- mice in the present study.   
Aside from measurements of liver steatosis and serum lipids, our study did not explore 
the potential contribution of altered lipid metabolism that might exist in these mice.  Lipotoxicity is 
a consistent feature of cardio-metabolic disease in both humans and animal models of obesity 
((71, 210-214)) and therefore may contribute to the severe liver and cardiac pathology observed 
in the obese GPx4+/- mice.  The obese GPx4+/- mice do not possess significantly greater 
adiposity than obese WT, as determined by % body fat. However, we cannot exclude that there 
may have been differences in adipose distribution between groups.  It is also known that GPx4 
directly modulates the lipoxygenase and cyclooxygenase II enzyme systems, and, when viewed 
in this context, the increased cardiac inflammation present in obese GPx4+/- mice supports a 
potential role for prostaglandins and other oxidized lipids in mediating the severe metabolic 
pathologies in this model.  Thus, we cannot exclude the contribution of these mediators in the 
obese GPx4+/- mice.  Other studies have documented that proteolysis and autophagy become 
compromised with carbonyl stress, and the diminished activity of these cellular processes may 
also explain the more severe phenotype observed in the obese GPx4+/- hearts ((215, 216)).  
None of these alternative pathways were explored in the present study.   
It is anticipated that these findings will serve to lay a foundation for future mechanistic 
studies directed at understanding how LPPs contribute to obesity-related pathologies and the 
adaptive role of GPx4.  Considering that the most severe effects observed in the obese GPx4+/- 
mice were evident in oxidative tissues (i.e., liver, heart, muscle), it will be very important in future 
studies to identify the cell- and tissue-specific role of GPx4 in mediating lipid peroxidation and 
carbonyl stress with obesity.  Furthermore, our findings have clinical implications as they suggest 
that patients exhibiting decreased GPx4 expression and activity might be predisposed to obesity-
related cardio-metabolic diseases.  Indeed, clinical studies and human cell models have shown 





((104, 184, 217-220)).  Finally, although our understanding of the role of lipid-derived aldehydes 
and carbonyl stress in the etiology of obesity-related diseases is in its infancy, it is important to 
recognize that compounds that scavenge HNE and other lipid-derived aldehydes specifically, 
such as histidine-containing dipeptides, may be very useful in this regard ((154, 156), 103) and 
have experienced some success in pre-clinical testing and even clinical trials  ((221-223)).  Thus, 
further research into novel therapeutics targeting carbonyl stress will be important for mitigating 
the numerous cardio-metabolic diseases that accompany this rising epidemic of obesity. 
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Weight   (g) 
34.5±1.3 48.0±2.2* 35.8±4.2 48.5±1.2*§ <0.0001 
Fat Mass    (g) 8.4±1.0 17.7±0.9* 10.0±2.9¤ 19.4±0.8*§ 0.0001 
Lean Mass (g) 21.6±0.4 26.0±1.2* 22.3±1.4¤ 24.9±0.4* 0.004 
Body fat    (%) 24.0±2.1 36.9±0.5* 31.3±3.0* 40.0±0.8*§ <0.0001 
Fasting glucose   
(mg/dL) 
141.3±4.1 168.6±14.2* 148.0±3.7 204.8±11.3*¤§ 0.007 
Cholesterol           
(mg/dL) 
51.0 ±8.6 72.8 ±6.5 34.0 ±8.7 103.5 ±17.8*§ 0.01 
Triglycerides        
(mg/dL) 
46.8 ±6.3 44.0 ±10.6 55.5 ±1.5 99.5 ±11.3*¤§ 0.003 
HDL Cholesterol  
(mg/dL) 
74.9 ±8.0 96.7 ±7.2 53.1 ±9.4 118.4 ±14.4*§ 0.009 
 
All values expressed as mean ± S.E.M., n = 4- 6. * P<0.05 vs. WT-CNTL vs. ¤ P<0.05 vs. 

























    Mean±SD 64±9.28         61±11 
0.49 




   Female 7 (14) 1 (2) 




   White 41 (84) 47 (87) 0.78 
  Black    8 (16)   7 (13)  
BMI    
   Mean±SD 31±6.6 30±5.3 0.46 
   Median (IQR) 30 (7.4) 29 (4.5)  
Preoperative Medications    
β‐blockers 34 (69) 41 (76) 0.87 
ACEi/ARBs 15 (31) 22 (41) 0.79  
Diuretics 21 (43) 20 (37) 0.69 
 CCBs 10 (20) 13  (24) 0.89  
Diabetic Medications 43 (88) 2 (4) <0.0001 
Insulin 32 (65) 2 (4)  
Metformin 15 (31) 0  
Sulfonylureas 4 (8) 0  
Glitazones 1 (2) 0  
GLP-1 agonist 2 (4) 0  
DDP-4 inhibitor 3 (6) 0  
Statins 41 (84) 46 (85) 0.94 
Nitrates 19 (39) 32 (59) 0.65 
Heart Failure 8 (16) 5 (9) 0.31 
LVEF (%) 
51.8 ± 
3.9 53.6 ± 6.4 0.87 
 





Table 3. Multivariable analysis of GPx4 and HNE-adducts in human heart 






RR (95% CI)‡ 
Mean±SD 6.2±4.2 8.7±5.9 
P=0.034† 
Median (IQR) 6.0 (5.2) 6.7 (6.6) 
  Q1 (≤3.9) 17 (35) 9 (17) 1.0    Referent 
  Q2 (>3.9 to 6.3) 10 (20) 15 (28) 0.65 (0.37 to 1.1) 
  Q3 (>6.3 to 9.4) 13 (27) 13 (24)  0.74 (0.47 to 1.2) 
  Q4 (>9.4) 9 (18) 17 (31)   0.58 (0.31 to 1.1) 
 
Ptrend =0.063†† 
HNE content (mM) 
Mean±SD 18±8.3 14±9.8 
P=0.028† 
Median (IQR) 16 (11) 11 (12) 
  T1 (≤9.0) 3 (10) 21 (47) 1.0    Referent 
  T2 (>9.0 to 17) 14 (47) 11 (24) 4.2 (1.4 to 13) 




‡        Relative Risk (RR) and 95% Confidence Interval (CI), adjusted for age and sex. 
†  P-value computed using Friedman’s Nonparametric test for central tendency, adjusting 
age and sex. 



















Figure 1.  Glycemic control and liver biochemistry/pathology.  Shown in A are oral 
glucose tolerance tests, along with fed-state serum insulin levels B after 24 weeks on the 
diet.  In C are representative immunoblots of GPx4 and HNE-adducts in liver from 4 
individual mice in each group, along with the corresponding β-actin loading control. 
Representative images of liver triglycerides stained with oil red O D, and collagen stained 
with picosirius red under polarized light E are shown for each group.  Images are 
representative of 16 image fields captured per mouse, n=2-3 mice per treatment group.  
Data shown as mean ± S.E.M., n = 7-8 mice per group. *P<0.05 vs. CNTL within genotype, 














Figure 2. Cardiac structural and functional parameters.  Panels shown are representative 
images of whole hearts A, cardiac collagen stained with picosirius red under polarized light B,C, 
and Masson’s Trichrome stained cardiac tissue D, from mice within each study group.  Shown in 
E are heart weight/tibia length ratio, cardiomyocyte diameter F, and serum BNP levels G.   
Cardiac contractility H, mean arterial pressure I, and heart rate J are shown for each group   
Images are representative of 16 image fields captured per mouse, n=2-3 mice per treatment 
group.  Data in E-J are shown as mean ± S.E.M., n = 6-8 mice per group. *P<0.05 vs. WT-CNTL, 



































Figure 3. Cardiac GPx4, protein carbonylation and redox signaling. Shown here is 
GPx4 mRNA expression A and protein content B in whole hearts from mice used in this 
study.  Representative immunoblot of HNE-adducts and hydrazide-labeled protein 
carbonyls C are shown from 3 individual mice in each group, Expression of redox and 
phase II detoxifying genes are shown in D.  Data shown in A & D are means ± S.E.M, n= 
5-7 per group. *P<0.05 vs. WT-CNTL, ¤ P<0.05 vs. WT-HFHS, § P<0.05 vs. GPx4+/--
CNTL.  CAT-Catalase; TrxII- Thioredoxin reductase II; GR- Glutatione Reductase; 
GPX1- Glutathione Peroxidase1; NQO1- NAD(P)H:quinine oxidoreductase; HO-1- Heme 










Figure 4. Cardiac mitochondrial GPx4 and functional parameters.  A representative 
immunoblot of GPx4 protein A and HNE-adducts B along with corresponding COX IV 
loading control are shown of isolated cardiac mitochondria obtained from mice used in 
this study.  In C are maximal ADP-stimulated rates of mitochondrial respiration (JO2) 
supported by Palmitoyl-L-carnitine in permeabilized cardiac myofibers from these mice.  
Shown in D are rates of mitochondrial H2O2 emission (mito-JH2O2) in phosphorylating 
state supported by Palmitoyl-L-carnitine + 100 µM ADP, in the absence (-) and 
presence (+) of the TxnRd2 inhibitor Auranofin.  Data shown in C & D are means ± 
S.E.M, N = 4-6 per group. *P<0.05 vs. all other groups for each respiratory state, † 
















Figure 5. Cardiac inflammatory and pro-fibrotic/hypertrophic gene expression.  
Expression of pro-inflammatory A, pro-fibrotic and hypertrophy genes B are shown in 
hearts from all four groups of mice in this study.  Β-MHC- β-Myosin Heavy Chain; 
Coll1a1-Collagen 1a1; Coll4a1-Collagen 4a1; TGFβ1 and 2 -Transforming Growth 
Factorβ 1 and 2; IL-β-Interleukin-1 Beta; IL-6 -Interleukin -6; TNF-α-Tumor Necrosis 
Factor- alpha; iNOS-Inducible nitric oxide synthase; RAGE- Receptor for Advanced 
Glycation End Products. All target genes normalized to 18S ribosome RNA. Data shown 
are means ± S.E.M, N = 4-6 per group. *P<0.05 vs. WT-CNTL, ¤ P<0.05 vs. WT-HFHS, 















Figure 6.  GPx4 content and HNE-adducts in human myocardium.  Total GPx4 
enzyme content A and HNE-adducts B are shown in atrial myocardium obtained from 
non-diabetic and diabetic patients undergoing elective heart surgery.  Shown in C is 
association between HNE-adducts and GPx4 enzyme in these heart samples, and the 
ratio of HNE-adduct to GPx4 enzyme are depicted in D.  Each symbol corresponds to 
one individual patient (N=103, see Table 2 for demographics and clinical variables).  P-
value computed using Friedman’s nonparametric test for central tendency, adjusting for 





































A novel carbonyl scavenging compound mitigates mitochondrial 
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In a previous study we reported that diet-induced obesity in a model of Glutathione Peroxidase 
4 (GPx4)-deficiency leads to exacerbation of cardiometabolic disease and mitochondrial 
dysfunction in the heart.  Carnosine is an endogenous alanyl-histidine dipeptide capable of 
neutralizing reactive aldehydes, however it is rapidly hydrolyzed by serum carnosinases and 
thus not suitable as a therapeutic.  Here we used a novel carnosine derivative carnosinol (CAR), 
an orally bioavailable compound which possesses an additional hydroxyl group and greater 
aldehyde reactivity, to determine if the aldehydes were the causative factor underlying the 
cardiometabolic derangements observed in the previous study.  .  
Methods WT and GPx4+/- mice littermates were fed a high fat high sucrose (HFHS) diet for 16 
weeks.  After 8 weeks on HFHS diet, half of the mice in each cohort were treated with CAR, a 
novel aldehyde-scavenging compound (40mg/kg in drinking water). 
Results   At the termination of the study, GPx4+/- mice were substantially more insulin resistant 
compared to WT.  CAR improved glucose tolerance by 60% and 22% in WT and GPx4+/- 
respectively. In soleus muscle (SOL), insulin-stimulated glucose uptake (ISGU) was ~80% lower 
in GPx4-HFHS vs WT-HFHS mice, and CAR had no effect on ISGU in either genotype.  In 
glycolytic extensor digitorum longus muscle (EDL), ISGU was not affected by genotype but CAR 
increased ISGU ~40% in both WT and GPx4 mice.  Hepatic steatosis was present following 
HFHS diet in both WT and GPx4+/-, although more pronounced in GPx4+/-mice.  CAR mitigated 
steatosis in both WT and GPx4+/-, although treatment was more effective in WT. CAR improved 
cardiac mitochondrial efficiency – the ratio of ATP production to O2 consumption and reduced 
H2O2 in WT groups.  However, although mitochondrial respiration capacity was increased in 
GPx4+/- HFHS, CAR group mitochondrial efficiency remained unchanged. 
Conclusion Collectively, these findings suggest 1) lipid peroxidation and subsequent aldehyde 






obesity, 2) GPx4 is a protective mechanism against this stress; and 3) aldehyde-scavenging 
compounds have clinical potential in obesity/diabetes.   
 
1. INTRODUCTION 
Lipid peroxidation of polyunsaturated fatty acids (PUFA) can lead to accumulation of α,β-
unsaturated aldehydes including 4 hydroxynonenal (4-HNE), malondialdehyde (MDA), acrolein 
and 4-hydroxy-2-Hexanal (HHE) (25, 47). Through mechanisms that involve the electrophilic 
attack of cellular components including enzymes and structural proteins, aldehydes have been 
implicated as key pathophysiological mediators of oxidative stress (25, 26, 47, 51, 227).  The 
main mechanism for clearance of lipid peroxides is reduction, which is, catalyzed by glutathione 
peroxidase 4 (GPx4) and to a far lesser extent though the phospholipase A-glutathione 
peroxidase 1 enzyme pathway (79, 86, 228, 229). Although the oxidative burden, which is 
classified by generation of oxidized glutathione (GSSG), is an order of magnitude greater with 
hydrogen peroxide (229), lipid peroxides induce prolonged effects on a cell. The aldehydes 
have a prolonged half-life and are capable of traversing cellular compartments. For this reason 
they have been called “toxic second messengers” (47). Nonetheless, aldehydes do have a 
critical role in normal signaling mechanisms. Therefore models such as the heterozygote GPx4 
mice (GPx4+/-) are useful to explore pathophysiological mechanisms that are triggered when 
reactive aldehyde species levels are elevated.  
 A number of studies have reported the involvement of LPPs specifically in 
cardiometabolic disease. Levels of aldehyde adducts are increased in both hearts of obese and 
diabetic human and murine models (23, 230) .  Aldehyde adducts are indeed biomarkers of 
oxidative stress, however in this capacity there is growing evidence to suggest these 






The development of compounds to scavenge these reactive aldehydes is a growing area of 
research. L- carnosine is an endogenous  alanyl-histidine dipeptide that has aldehyde 
scavenging properties (145, 232) . It is present in muscle at high concentrations and is thought 
is have aldehyde-sequestering function there,  however its precise function remains unknown 
(145). Muscle carnosine levels are depleted in type II but not type I diabetic patients, suggesting 
that it may be involved in a compensatory response in metabolic diseases (233).The 
exploitation of the scavenging properties of carnosine in the body are limited by the fact that it 
rapidly hydrolyzed by serum carnosinases (147, 149). A number of studies have utilized 
carnosine analogs in models of metabolic disease. In ApoE (-/-) mice, carnosine treatment 
stabilized atherosclerotic plaques (155). A D- carnosine octylester was shown to be protective 
against atherosclerosis and markers of renal disease in ApoE (-/-) (152).  Although, the D-
enantiomer is not recognized by serum carnosinases allowing for a longer half-life, it has 
extremely low bioavailability as it is not recognized by the intestinal drug oligopeptide 
transporter  hPepT1 (147, 152). To address this problem, Carnosinol, orally bioavailable 
compound, which possesses an additional hydroxyl group and greater aldehyde reactivity, was 
used (147, 152, 234). The hydroxyl moiety, which shields carnosinol from hydrolysis from serum 
carnosinases. In addition, carnosinol has increased activity due to the higher nucleophilicity of 
the imidazole ring. Preliminary pharmacokinetic studies of carnosine demonstrate there it is 
associated with no cytotoxicity or induction of CYP450s, low plasma protein binding and high 
bioavailability (Data, not shown).  In this study, we used this novel compound carnosinol, to test 
the hypothesis that scavenging LPPs would rescue cardiometabolic derangements in obesity by 









2. MATERIALS AND METHODS 
2.1 Experimental Model and Study Design.  Approval was obtained from the institutional 
animal care and use committee of East Carolina University for all procedures performed in 
compliance with the National Institutes of Health’s Guide for Care and Use of Laboratory. 
C57BL6/J male mice (Jackson Laboratory) were crossed to GPx4+/- females. (82). At 8-12 
weeks, WT and GPx4+/- male age matched littermates (n=8) were randomly assigned to groups 
and individually housed. Mice were fed either control (CNTL-TD110367) or two groups of high 
fat high sucrose (HFHS-TD110365) diet from Harlan-Teklad Laboratories (Madison, WI) ad 
libidum for 18 weeks. The composition of this diet has been described previously (72).  Mice 
were housed at controlled temperature and a 12hr light/dark cycle was maintained.  At 8 weeks 
one of the WT HFHS and GPx4 +/- HFHS groups were administered carnosinol at 40mg/kg in 
the drinking water ad libidum. 1-2 weeks before  tissue collection all live animal metabolic and 
echocardiographic measurements were made to allow the animals to reacclimate  to minimize 
the effect of stress that may have been introduced by these procedures. 
 
2.2 Metabolic Parameters. Total body weight, food and water consumption was recorded on 
bi-weekly basis for the duration of the study Nuclear- MRI was used to assess body composition 
at 8 and 16 weeks (EchoMRI 700 Echo Medical Systems, Houston, TX).  Following a ~4 hour 
fast at 8 and 16 weeks an oral glucose tolerance (dose-0.5g/kg) was performed on the cohorts. 
Blood was obtained as described previously standard glucometer (LifeScan, Milpitas, CA).  
Indirect calorimetry was performed. Mice were single housed in metabolic cages (TSE Systems) 
for 4 days after 16 weeks on the diet. TSE Software was set to record parameters including 
maximal O2 consumption (VO2), CO2 production (VCO2) at 20 minute intervals. The average of 
two complete light and dark cycles was calculated. Insulin stimulated 2-deoxyglucose (2-DOG) 






muscles were incubated in Krebs-Henseleit buffer (KHB) in the presence of insulin. Muscles 
were then rinsed then incubated with KHB that contained 2-DOG. Muscles were incubated for 
30 minutes then blotted and flash frozen.  Muscle was homogenized then levels of 2-DOG were 
measured. 
2.3 Assessment of Cardiac Function.  Blood pressure was measured by non-invasive tail-cuff 
plethysmography (SC1000, Hattaras Instruments, Cary, NC).  The detailed procedures have 
been described in the previous chapter. 
 
2.4 Liver and Cardiac Histology:  Mice were anesthetized with isoflurane. Hearts (n=2) were 
infused with paraformaldehyde then fixed with paraffin. Histological measurements were 
measured using (http://imagej.nih.gov/ij/)  the details of processing and staining have been 
described in the previous chapter. 
 
2.5 Preparation of permeabilized cardiac myofibers and mitochondrial function 
measurements.  Cardiac muscle was processed exactly as described in (22-24, 72) Katunga et 
al., in press.  Fibers were weighed before experiments and once mitochondrial experiments 
completed, fibers were collected, rinsed, lyophilized (Labconco, Kansas City, MO) then 
weighted on a microbalance (Mettler Toledo, Denver, CO). 
 
2.6 Mitochondria Isolation.  Methods used were modified form (225, 226).  Briefly, 
approximately 100 mg of cardiac tissues was excised, minced then incubated in trypsin.  
Remaining mixture was resuspended in 3mL of Mitochondria Isolation Medium (MIM) (300mM 
Sucrose, 10mM Na-HEPES, 0.2mM EDTA) with BSA then homogenized. The homogenate was 
then subjected to a series of centrifugation steps. The final mitochondrial fraction was frozen 







2.7 Immunoblot analysis of protein content. Homogenized tissue was loaded in 12% 
polyacrylamide SDS gel (Bio-Rad, Hercules, CA). Protein was transferred to PVDF membranes 
(Millipore, Bellerica, CA) and incubated with primary antibodies for GPx4, COXIV, β-actin and α-
tubulin (Abcam, Cambridge, UK) and 4 HNE (Peptisico).  Membranes were incubated using 
infrared fluorophore-conjugated secondary antibodies (LiCor Biosciences, Lincoln, NE), 
scanned using Odyssey Clx Infrared Imaging System (Li-Cor) and analyzed by densitometry 
using Image J (NIH). 
 
2.8 Statistical Analysis.  Data are presented as mean ± SEM. Statistical analysis were 
performed with Graph Pad Prism (Graph Pad Prism, La Jolla, CA). Two way ANOVA was 
performed on continuous variables followed by Sidak multiple comparison’s test unless 
otherwise stated, with α< 0.05 considered statistically significant.  
 
3. RESULTS 
3.1 Carnosinol improves glucose tolerance and insulin sensitivity in WT following a high 
fat diet. We have described the rationale behind the use of the GPx4 +/- mouse as model of 
increased LPPs in cardio-metabolic disease in the previous chapter. The goal of this study was 
to determine whether CAR could rescue cardiometabolic perturbations and using the GPx4+/- 
mouse to understand the extent to which these characteristics maybe attributed to elevated 
levels of carbonyl stress. There were no significant differences between WTs and GPx4+/- mice 
with diet or treatment in weight gain (Figure 1a), terminal body weight (Figure 1b) or adiposity 
(Table 1). Glycemic control as assessed following an oral glucose challenge at 16 weeks 
(Figure 1c) following intervention CAR rescues glucose tolerance to levels similar in WT CNTL 
group. However, AUC for GPx4+/- on a HFHS is greater than WTs (Figure 1d) and this is only 






effect is more pronounced in the EDL (Figure 1f) compared to the Soleus (Figure 1g). Serum 
Insulin levels (Figure1h) reveal a trend of increased insulin in GPx4 on diet compared to WT 
and across genotypes CAR treatment decreases fasted insulin levels, although this does not 
yield statistical significance. 
 
3.2 Whole Body Indirect Calorimetry Changes in VO2, CO2 and RER values are shown in 
(Figure 2a-c), the average of these values is presented for light and dark cycles in (Figure2d-f). 
There were slight differences within genotypes for VO2 (Figure 2d) during the dark cycle 
otherwise whole body energy expenditure remained unchanged. 
 
3.3 Carnosinol treatment reduces lipid peroxidation and ameliorates hepatic steatosis. 
GPx4 enzyme levels were increased with both the diet but even more so with CAR treatment 
(Figure 3a.). The effect was greater in WT compared to GPx4 mice. Levels of 4-HNE adducts 
are shown in (Figure 3b). HNE-adducts are increased with the diet, even more so in GPx4+/- 
HFHS group. Levels of 4-HNE adducts are reduced with CAR treat in both WTs and GPx4+/- 
mice. Hepatic liver steatosis is presented in (Figure 3c). In WTs CAR appears to reduce the 
size and increase dispersion of lipid droplets in the liver.  However, this effect is absent in 
GPx4+/- mice. This is reflected changes in liver triglycerides shown in (Figure 3e). There were 
only marginal changes in fibrosis (Figure 3d) 
 
3.4-5 Cardiac remodeling Morphology of cardiomyocytes is presented in Figure 4. As 
expected, HFHS induced an increase in cardiomyocyte diameter (Figure 4a). This was 
mitigated with CAR treatment. Cardiac fibrosis is presented in (Figure 4b). HFHS diet resulted 
in cardiac hypertrophy (Figure 5a), which was slightly decreased in WT with CAR. However 






5b). There were no or only marginal changes in Mean arterial pressure (Figure 5c), heart rate 
(Figure 5d), systolic blood pressure (Figure 5e), diastolic blood pressure (Figure 5f). 
 
3.6 Cardiac GPx4 protein levels and 4-HNE adducts Levels of GPx4 protein in heart tissue 
are presented in (Figure 6a). CAR treatment appears to have a greater effect on increasing 
GPx4 expression in GPx4+/- mice compared to WTs. 4-HNE levels are globally increased with 
HFHS diet, however CAR treatment has a greater effect on reduction of 4-HNE adducts in WTs 
compared to GPx4s (Figure 6b). 
 
3.7 Mitochondrial efficiency improved and levels of carbonyl adducts reduced with 
carnosinol treatment. Mitochondrial parameters are presented in (Figure 7). Mitochondrial 
respiration with pyruvate/ malate as a substrate is presented in (Figure 7a). HFHS diet is 
associated with a decrease slight increase in respiration in WTs but an increase in GPx4+/- 
mice. Surprisingly CAR treatment appears to result in a reduction in respiration in WTs. 
Conversely in GPx4 mitochondria CAR treatment results with increased mitochondrial 
respiration. ATP production is presented in (Figure 7b) reveals with the HFHS diet, ATP 
generation is decreased however, CAR treatment improves ATP production. Mitochondrial 
efficiency presented as the ATP/O ratio in (Figure 7c) shows CAR improves ATP/O ratio in WT 
but not in GPx4+/- mice. Mitochondrial dysfunction as measured by H2O2 emission production 
capacity was measured and presented in (Figure 7d) in the presence and absence of auranofin 
the thioredoxin reductase-2 (TxnRd2) inhibitor. H2O2 emission was slightly reduced in the HFHS 
diet however H2O2 levels in CAR treatment were similar to CNTL. In the presence of auranofin, 
H2O2 was only slightly higher in the HFHS group compared to CNTLs.  Levels of H2O2 are  
reduced almost by 25% in the CAR treated group. In contrast, H2O2 levels are increased with 
the HFHS diet in GPx4+/- mice and CAR treatment only marginally decreased H2O2 emission. In 






treatment reduced H2O2 emission by ~30% compared to the HFHS group. The levels of HNE 
adducts in the mitochondrial fraction are presented in (Figure 7e).  The mitochondria of 
GPx4+/- mice contain significantly higher levels of HNE adducts almost comparable to WT 
HFHS group. CAR reduces the levels of HNE adducts in the mitochondrial fraction, however 
level of HNE adducts are only marginally increased in GPx4+/- HFHS CAR group. 
 
4. DISCUSSION 
Carnosinol is a novel histidine-containing dipeptide alcohol that is highly reactive with lipid-
derived aldehydes, and is capable of sequestering reactive aldehydes such as HNE, 
malondialdehyde and acrolein, thereby reducing their steady-state concentrations in vivo.  The 
objective of the present study was to use this compound as an intervention to determine 
whether reducing aldehyde levels in a HFHS diet-induced model of obesity, would mitigate the 
deleterious effects of obesity on cardiometabolic disease parameters.  In particular, the effect of 
CAR on cardiac hypertrophy/fibrosis, and mitochondrial oxidative phosphorylation (OxPhos) 
efficiency was examined.  In a recent study of human skeletal muscle, there was a positive 
correlation between levels of carbonylated proteins and intramyocellular lipid content (235). 
Together these parameters were inversely related to glycemic control. In a study that assessed 
the effects of 4-HNE treatment on skeletal muscle insulin sensitivity, the effect of 4-HNE was 
time and dose dependent reduction in insulin signaling at levels that had cytotoxic effect (236). 
In an elegant study conducted by Cohen et al., HNE was shown to exaggerate glucose –
stimulated  insulin section through direct action as a ligand for peroxisome proliferator-activated 
receptor- δ (PPAR- δ) (237). 
Our study coincides with other studies that show that increased carbonyl adducts with 
insulin resistance in both murine and human models. These findings lend empirical support to 






rescue insulin resistance may occur through a number of mechanisms. In high fat fed mice, 
GPx4 overexpression protected from insulin resistance and β- cell dysfunction (238). It is 
plausible that CAR, as an exogenous agent, is working in a similar manner. The effect of 
carnosine analogs on insulin resistance appears to be highly dependent on the model used to 
induce steatosis. For instance, with high fructose diet, carnosine had no effect on insulin 
resistance and triglyceride levels, whereas in a model fed a 60% HF lard diet these parameters 
were improved (239, 240).  
Preceding studies support the observation that CAR mitigates hepatic steatosis.  In a 
study where rats were fed a 60% fructose diet and treated with 2g/L carnosine in their drinking 
water, hepatic steatosis and LPPs levels measured by MDA and diene conjugates were 
reduced. The addition of α-tocopherol had a synergistic effect (239). One possible explanation 
for the reduction in hepatic steatosis is a down regulation of lipogenic enzymes in the liver. In 
mice fed a 60% high fat diet with1g/L carnosine for 8 weeks, carnosine reduced the activity and 
mRNA expression key enzymes such as malic enzyme, fatty acid synthase, 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) as well as sterol regulatory element-binding proteins 
(SREBPs) in liver and adipose tissue (240). 
Mitochondrial dysfunction has been implicated in the etiology of insulin resistance and 
T2DM (15, 24).  Numerous studies have demonstrated that aldehydes reduce mitochondrial 
“bioenergetics reserve” (191). The decline in mitochondrial efficiency may also be explained by 
decline in efficiency of mitochondrial components. Carbonyl modification of uncoupling proteins 
has been shown to increase their permeability of protons, thus reducing mitochondrial efficiency 
(241). LPPs directly inhibit the adenine nucleotide translocase (242). Alternatively, increased 
respiration in GPx4+/- HFHS mice may be due to induction of mitochondrial biogenesis (243). 
The findings of our studies may also be explained by mitochondrial uncoupling in the GPx4+/- 
mice. This is in line with studies in the Db/Db model in which mitochondrial proliferation was 






mediated by uncoupling proteins, which may explain our observations (244).  One limitation of 
this study is that a detailed assessment of diastolic function in the mice was not obtained.  
 There is little doubt in our mind that diastolic function is impaired in these mice, however, 
given the findings of Colucci’s group and Taegtmeyer’s group (185, 245)  using identical diet-
induce obese models.   It is important to note that HNE has been shown independently to impair 
ion homeostasis leading to increased intracellular Ca2+ in neurons.  It is plausible that HNE may 
impair diastolic function through similar mechanisms (246). Previous studies have shown that 
treatment of cardiomyocytes with HNE also reduce cardiomyocyte contractility (247).  
Our study provides evidence that CAR treatment induces the expression of GPx4 in the liver 
and heart. This suggests that CAR treatment may induce beneficial effects not only directly 
through the scavenging of LPPs, but indirectly through increasing the antioxidant capacity of 
tissues. In several studies of CAR treatment in xenobiotic toxicity models of extreme antioxidant 
stress, levels of glutathione (GSH), antioxidant enzymes including superoxide dismutase, 
glutathione peroxidase expression and activity were either increased or restored to basal levels 
(248). 
It is important to acknowledge the exploratory nature of this study and the limitations of 
this pilot study. This study did not evaluate mitochondrial structure (e.g. fission/fusion 
parameters, electron microscopy), or how these parameters may be altered with carnosinol 
treatment. Although this was outside the scope of this study, we acknowledge the contribution of 
lipid peroxidation to membrane fluidity (249) and structure, which is a critical component to 
membrane integrity. Markers of cellular turnover and autophagy were not measured in this study 
however HNE was been shown to activate autophagy. (75, 215). 
In conclusion, here we present a novel therapeutic CAR that mitigates the metabolic 
syndrome in a model of obesity in WT and GPx4+/-  mice. Previous studies have demonstrated 
that the metabolism of HNE is influenced by age, NAD+ metabolism and complex I activity. 
































Weight   (g) 30.1±1.2 49.7±1.0* 45.7±2.3* 29.7±0.9 48.5±2.4§ 46.8±3.1§ <0.0001 
Fat Mass    (g) 6.2±0.9 5.5±0.7* 19.8±1.3* 5.5±0.7 18.2±1.2§ 18.2±1.3§ <0.0001 
Lean Mass (g) 22.0±0.4 25.7±0.9* 24.6±1.1* 21.5±0.3 24.4±1.2§ 24.1±1.4§ 0.003 
Body fat    (%) 19.7±2.1 42.7±0.7* 42.7±1.4* 18.2±1.7 41.8±1.2§ 42.2±1.8§ <0.0001 
 
All values expressed as mean ± S.E.M., n = 6-8. * P<0.05 vs. WT-CNTL vs. ¤ P<0.05 vs. WT-HFHS. § P<0.05 vs. GPX4+/- CNTL. 




















Figure 1. Body composition, glycemic control and insulin resistance. Weight change over 
16 weeks is presented in A with terminal body weight at the end of the study in B. Oral glucose 
tolerance is shown at 16 weeks, 8 weeks after carnosinol intervention for C WTs and D  GPx4 +/- 
mice. AUC is quantified in E. The total uptake of 2-DOG following an insulin exposure in whole, 
intact soleus F and Extensor Digitoum Longus G skeletal muscles prepared from the cohorts of 
mice in this study (n=5-6). Serum insulin levels are presented in H. Data are shown as ± S.E.M. 
using two-way ANOVA followed by Sidak’s multiple comparison test. *P<0.05 vs. WT-CNTL, ** 































 exchange. Metabolic activity was measured via indirect 
calorimetry of A) maximal O2 consumption (VO2) and B) CO2 consumption (VCO2) C) RER was 
calculated as VCO2/O2 are presented as a function of time over the dark and light cycles. D) 
VO2 E) VCO2 and F) RER show average mL of gas consumed/ expelled per hour normalized to 
body weight. Data are shown as ± S.E.M. two-way ANOVA followed by Sidak’s multiple 
































Figure 3. Liver Histology. Shown in A is a representative immunoblot of GPx4 and B. HNE- 
adducts in liver with B actin as the loading control (n=4). C. Representative images of liver 
stained with Oil Red O for triglycerides C and collagen stained with picosirus red under 
polarized light D is shown for each group.  E.  Levels of liver tissue triglycerides. Data are 
















Figure 4. Cardiac Histology. Panels shown are representative images of cardiac section 















Figure 5. Cardiac function parameters. A. Cardiac hypertrophy as measured by heart 
weight/ tibia ratio. B. Cardiomyocyte diameter quantified from slides of cardiac tissue. 
Parameters of heart function are shown C. Mean Arterial Pressure. D. Heart rate, E. Systolic 
Blood Pressure, F. Diastolic Blood Pressure. Data are shown as ± S.E.M. Analysis two-way 
ANOVA followed by Sidak’s multiple comparison test. *P<0.05 vs. WT-CNTL, ** vs. WT-HFHS. § 






















Figure 6. Cardiac GPx4 and protein carbonylation. Shown in A. is a representative image of 
































Figure 7.  Mitochondrial respiratory capacity and function in cardiac muscle following 
HFHS diet. Rates of mitochondrial O2 consumption ( JO2) in maximal ADP-stimulated 
conditions are shown for cardiac tissue supported by complex I and II substrates 
pyruvate/malate and succinate are shown in A. B Rates of mitochondrial O2 consumption at 
submaximal ADP (75mM) and corresponding levels of ATP generated. C. Mitochondrial 
efficiency as represented by the ratio of ATP generated to oxygen consumed ATP/O ratio is 
presented  D. Rates of mitochondrial H2O2 emission (mito-JH2O2) in the presence of succinate 
are shown for cardiac tissue in the presence and absence of Thioredoxin Reductase inhibitor 
auranofin (n=6). E Representative immunoblot of mitochondrial HNE adducts. Data are shown 
as ± S.E.M.  #P<0.05 for Auranofin effect with Paired t-test. Two way ANOVA followed by 
Sidak’s multiple comparison test. *P<0.05 for Genotype effect within treatment, †P<0.05 for 












The prevalence of global cardiovascular disease is increasing exponentially. Accordingly, there 
is an urgent need from both a clinical and public health perspective to improve our 
understanding of the underlying etiology of this disease. It is widely accepted that oxidative 
stress is a major driving mechanism in heart disease. For decades, levels of lipid-derived 
aldehydes such as HNE and MDA have served as biomarkers of oxidative stress, however the 
contribution that these signaling molecules make as specific causal factors in the development 
of disease was unclear. Collectively, the body of work presented in this dissertation sought to 
begin to address this gap in knowledge. The overall objective of this dissertation was to 
determine the role of LPPs in the development of cardio-metabolic perturbations observed in the 
obese insulin resistant heart.  
In the first study, the GPx4+/- mouse was employed as model of increased LPP 
production. This was the first time that the effects of nutrient overload were assessed in this 
mouse model. The findings of this study support that elevated LPPs are indeed significant 
etiological factors in the progression of cardio-metabolic disease. Furthermore, we provide 
evidence of the significance of the GPx4 as a cardio-protective enzyme in the human heart. 
Prior to our work, GPx4 was implicated to play a role in through inferences made in Kashin-beck 
heart patients but this is the first time that its role has been demonstrated in a subset of clinical 
patients. Thus these findings make constitute a significant contribution to the existing knowledge 
base.
Together these data served to validate the GPx4+/-  mice HFHS fed mouse as a model to 
evaluate the influence of elevated LPPS on signaling mechanisms involved in cardio-metabolic 
disease. In addition, this study described a novel protective role of GPx4 in cardiometabolic 






The mitochondria from GPx4+/- mice possessed a higher H202 emission capacity, which 
would be expected to result in greater initiation events in lipid peroxidation ultimately resulting in 
carbonyl stress. The association between poor glycemic control and lower activity of 
mitochondrial enzymes due LPP modification was widely reported.  This had never been 
described in the HFHS-fed GPx4+/- model and this provides data highlighting new mechanisms 
that provide possible explanations of how these changes occur.  
The protective role of GPx4 in cardio-metabolic disease is highlighted by the worsened 
metabolic phenotype in GPx4+/- mice on a HFHS diet. After a long-term HFHS diet, GPx4+/- mice 
were significantly more insulin resistant with worsened hepatic steatosis. This highlights a 
previously unidentified role for GPx4 in preventing metabolic syndrome. Chronic low-grade 
inflammation also known as meta-inflammation is a hallmark of metabolic syndrome. Messenger 
RNA data that shows higher levels of pro-inflammatory markers in GPx4+/- HFHS fed mice. 
Although a role for GPx4 in the regulation of inflammation has been proposed this is the first 
time it has been validated in a model of metabolic disease.  
Histological assessment of the hearts of GPx4+/- mice show increased collagen 
deposition and cardiomyocyte hypertrophy.  In a translational step of this study, we examined 
whether these mechanisms occurred in human atrial appendage tissue of diabetic patients 
undergoing coronary artery bypass surgery. Numerous groups have reported increased HNE 
modifications in the hearts of diabetic patients. GPx4 levels had never been reported in the 
hearts of diabetic patients. Here we report for the first time an association between cardiac 
GPx4, cardiac HNE-adducts and diabetes status. This study provides a foundation for the 
identification of a novel sub-set of patients that may benefit from a novel therapeutic strategy to 
quench LPPs. These findings served as a foundation for a second series of studies that 






A number of studies have explored the use of carnosine analogs in metabolic syndrome. 
However, the endpoints of these experiments have been on renal and atherosclerosis. Our 
study presents a comprehensive report of cardiometabolic endpoints using the novel compound 
carnosinol in a model of obesity.  Carnosinol improved glycemic control and insulin sensitivity in 
WT mice on a HFHS diet. The effect of carnosine analogs on insulin sensitivity had not been 
reported before.  These beneficial effects were marginal or not present in GPx4+/- mice on the 
drug. Carnosinol treatment improved hepatic steatosis by reducing the levels of triglycerides. An 
intriguing finding of this study was that carnosinol reduced cardiomyocyte and whole heart 
hypertrophy in WT and GPx4+/- mice respectively.  As expected levels of 4-HNE adducts were 
reduced in mitochondrial fraction as well as heart and liver tissues. These data also show that 
carnosinol is capable of penetrating the mitochondrial compartment. Diminished 4-HNE adducts 
in the mitochondria were accompanied by changes in mitochondrial function. In WT mice, 
carnosinol treatment improved mitochondrial efficiency in heart, however in obese GPx4+/- mice 
there was an increase in respiration with little change in ATP production. This is the first time 
that the effect of a carnosine analog on mitochondrial function in a model of metabolic syndrome 
has been reported. This study also revealed an additional mechanism through which carnosine 
analogs may improve redox capacity by increasing the expression of antioxidant enzymes 
including GPx4. 
 In conclusion, the body of work presented in this dissertation provides evidence for a 
specific role of LPPs in the etiology cardio-metabolic disease, and that the use of a novel class 
of aldehyde-scavenging compounds may have unique therapeutic benefit obese/diabetic 
patients. Together these data provide a foundation for future pharmacological and experimental 














Figure 4.0: This schematic of the two approaches used to test the effect of LPPS on the 
heart in diet-induced obesity. 
Model of increased 
carbonyl stress: HFHS 

















Model of decreased carbonyl 
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